EADO European Association of Dermato Oncology

3 - 6 May 2017 Athens Greece Megaron Athens International Conference Centre

FINAL PROGRAMME

Visit BMS at Booth No 5 to learn more

Bristol-Myers Squibb A.E. Attica 49-53 & Propontidos 2, 152 35 Vrilissia, P.O. Box 63883 - 152 35 Vrilissia Attica Tel: +30 210 60 74 300 & +30 210 60 74 400, Fax: +30 210 60 74 333 G.E.MI 7453601000 Before prescribing please consult the SmPC that is provided by the Marketing Authorization Holder.

You can help make medicines safer by reporting all adverse events for all medicines, by completing the ‘Yellow Card’

7356GR1700165-01 03/17 © 2017 Bristol-Myers Squibb Company. www.eado2017.org OPDIVO® and YERVOY® and the related logos are trademarks of Bristol-Myers Squibb Company.

106271 EADO Athens Programme Book Advert v3.0 2017.03.16.indd 1 27/03/2017 09:59 A Roche-sponsored satellite symposium at the European Association of Dermato Oncology 2017

CONTENTS SHAPING THE FUTURE WELCOME ADDRESS...... 3 COMMITTEES...... 4 TOGETHER GENERAL INFORMATION...... 5-8

SOCIAL PROGRAMME...... 8

Scientific Information...... 9-10

SCIENTIFIC PROGRAMME Wednesday, May 3, 2017 TREATMENT OF PROGRAMME OVERVIEW...... 11 PROGRAMME ...... 12-15 METASTATIC Thursday, May 4, 2017 MELANOMA PROGRAMME OVERVIEW...... 16

PROGRAMME ...... 17-23

FRIDAY, May 5, 2017 Friday, 5 May 2017 | 12:45–13:45 | Banquet Hall PROGRAMME OVERVIEW...... 24 Megaron Athens International Congress Centre PROGRAMME ...... 25-32 Chaired by Georgina Long, Melanoma Institute of Australia, Australia Saturday, May 6, 2017 PROGRAMME OVERVIEW...... 33 12:45–12:55 What does the future look like for patients with metastatic melanoma? PROGRAMME ...... 34-36 Georgina Long, Melanoma Institute of Australia, Australia

12:55–13:05 Combining targeted therapy with immunotherapy: A rational approach Free Communications Catalogue ...... 38-42 Peter Mohr, Elbekliniken Stade Buxtehude, Germany e-Posters Catalogue ...... 43-58

Index of Speakers, Chairpersons & Authors ...... 59-70 13:05–13:15 Targeted therapy and immunotherapy, a potential combination for the future: The early clinical evidence Sponsors & Exhibitors section Paolo Ascierto, IRCCS National Tumour Institute Fondazione G Pascale, Italy 13:15–13:45 Achieving the best outcomes in metastatic melanoma today: acknowledgements ...... 72 The experts’ experience Corporate Profiles ...... 73-76 Helen Gogas, University of Athens, Greece Sponsored Sessions Peter Mohr, Elbekliniken Stade Buxtehude, Germany Paolo Ascierto, IRCCS National Tumour Institute Fondazione G Pascale, Italy Wednesday, May 3, 2017 ...... 77-78 Facilitated by Georgina Long Thursday, May 4, 2017 ...... 78-79

FRIDAY, May 5, 2017 ...... 79

Exhibition Floor Plan ...... 80-81 NP/COBI/1703/0001d melanoma_3_0417 Date of Preparation April 2017 EADO European Association of Dermato Oncology WELCOME ADDRESS WELCOME ADDRESS

Dear Colleagues,

It is a great pleasure to welcome you to the 13th Congress of the EADO. The Congress is organised by the European Association of Dermato-Oncology (EADO), a leading international organisation in the field of skin cancer and melanoma. As a wealth of new information is arising from the rapidly evolving field of cutaneous oncology, the 13th Congress of the EADO aims to provide you with a comprehensive overview of the most recent advances in the prevention, diagnosis and treatment of melanoma and non-melanoma skin cancers. During the Congress you will have the opportunity to attend state-of-the-art presentations given by leading experts of the field and to participate in informative discussions covering the entire spectrum of cutaneous malignancies, including melanoma, cutaneous lymphoma, epithelial skin cancers and other skin tumours. Plenary lectures, interactive symposia and workshops will focus on the most current and controversial topics of dermatologic oncology, from the epidemiology, biology and genetics of melanoma to the results of the most recent therapeutic trials and translational research on malignant skin tumours. In addition, abstract sessions will offer a unique opportunity to discuss your work with faculty and congress participants. The ultimate goal of the Congress is to enhance your knowledge with up-to-date information and address important issues that will assist you on your everyday management of patients with melanoma and other malignant skin tumours. The Congress will also offer a capacious industrial exhibition, which we invite you to visit. We welcome you to the exciting and cultural city of Athens for an event that promises to be a valuable scientific exchange. Your participation and input will add immensely to the goals of this international multidisciplinary Congress. Welcome to Athens!

Alexander J. Stratigos, MD Congress Chairman Professor of Dermatology & Venereology Department of Dermatology University of Athens Medical School

PB 13th Congress of the EADO • Athens, Greece Final Programme 3 COMMITTEES

EADO ORGANISATION European Association of Dermato Oncology

EADO EXECUTIVE COMMITTEE President: Claus Garbe, Tuebingen, Germany Vice-President: Alexander J. Stratigos, Athens, Greece Treasurer: Axel Hauschild, Kiel, Germany General Secretary: Ketty Peris, Rome, Italy Secretary for members: Josep Malvehy, Barcelona, Spain Secretary for European integration: Anna-Maria Forsea, Bucharest, Romania Past President: Jean-Jacques Grob, Marseille, France Past President: Hubert Pehamberger, Vienna, Austria

ORGANISING COMMITTEE Chairman: Alexander J. Stratigos, Athens, Greece Members: Claus Garbe, Tuebingen, Germany Jean-Jacques Grob, Marseille, France Hubert Pehamberger, Vienna, Austria Ketty Peris, Rome, Italy Axel Hauschild, Kiel, Germany Josep Malvehy, Barcelona, Spain Anna-Maria Forsea, Bucharest, Romania

ABSTRACTS REVIEW COMMITTEE POSTER AWARDS REVIEW COMMITTEE Clio Dessinioti, Athens, Greece Veronique Bataille, Hemel Hempstead, Vasiliki Nikolaou, Athens, Greece United Kingdom Ioanna Panoutsopoulou, Athens, Greece Véronique del Marmol, Brussels, Belgium Efthymia Soura, Athens, Greece Roland Kaufmann, Frankfurt, Germany

UNDER THE AUSPICES OF:

HELLENIC ASSOCIATION FOR THE STUDY OF MELANOMA

4 13th Congress of the EADO • Athens, Greece Final Programme 5 EADO European Association of Dermato Oncology COMMITTEES GENERAL INFORMATION

CONGRESS VENUE MEGARON ATHENS INTERNATIONAL CONFERENCE CENTER (MAICC) Vass. Sofias & Kokkali, 115 21 Athens, Greece Call Center: +30 210 7282000, Fax: +30 210 7290174 Website: www.maicc.gr

CONGRESS ORGANISING BUREAU ERASMUS CONFERENCES TOURS & TRAVEL S.A. 1, Kolofontos & Evridikis str., 161 21 Athens, Greece Call Center: +30 210 7414700, Fax: +30 210 7257532 E-mail: [email protected], Website: www.erasmus.gr

REGISTRATION DESK The Registration Desk is located at the N. Skalkotas level (-1) of the Megaron Athens International Conference Centre and will be in operation the following dates and hours: Wednesday, May 3, 2017 11:00 -19:00 Thursday, May 4, 2017 07:30 -19:00 Friday, May 5, 2017 07:30 -18:30 Saturday, May 6, 2017 08:00 -12:00

BADGES The name badge issued to delegates upon their check-in at the Registration Desk serves as an admission pass to all scientific sessions and to the exhibition. Delegates are kindly requested to make sure that they wear their name badges at all times. Badges categories: Faculty members RED Delegates WHITE Industry Participants GREEN Exhibitors ORANGE

EADO INFORMATION DESK The information desk of the European Association of Dermato-Oncology (EADO) is operating in the Exhibition area of the congress venue (booth 8B) on Thursday, May 4 and Friday, May 5 from 09:00-14:00.

4 13th Congress of the EADO • Athens, Greece Final Programme 5 EXHIBITION The exhibition is located in the foyer of “N. Skalkotas” hall, and will be operating according to the following schedule: Wednesday, May 3, 2017 12:00 -20:00 Thursday, May 4, 2017 09:00 -19:00 Friday, May 5, 2017 09:00 -19:00 Saturday, May 6, 2017 08:00 -13:30 Details of the exhibiting organisations and companies can be found on pages 72-76.

INSURANCE Neither the Organising Committee nor the Congress Organising Bureau accept any liability for damages and/or losses of any kind which may be incurred by the Congress participants or by any persons accompanying them, both during and outside the congress programme and activities. Participation in all tours and events is at one’s own risk. Participants are advised to take out insurance against loss, accidents or damage that could be incurred during the Congress. Verbal agreements will not be binding unless they are confirmed in writing. Sole place of jurisdiction is Athens. Greek law is applicable.

CAR PARKING There is an underground passenger car park available providing parking lot for 750 cars. It is open daily from 06:00 a.m. until 02:00 a.m.. Entrance via Kokkali Street. The special congress rate is €12 per day for multiple entries per day, prepaid upon entry. Standard parking rate is €3 for the first 3 hours and €1 per hour thereafter. There is no parking available for large vans/trucks/lorries.

CASH MACHINE The nearest ATM machine is located inside the Megaron Athens International Conference Centre, at the main entrance of the building.

CREDIT CARDS Commonly accepted credit cards in hotels, restaurants and stores are American Express, Visa and MasterCard.

FIRST AID First aid with a fully qualified nurse is available. It is located on Muses Foyer level, towards Kokkali street and operates on the actual days of the event including building-up and dismantling days.

INTERNET FACILITIES Free WiFi internet connection will be available in the venue via the EADO network.

6 13th Congress of the EADO • Athens, Greece Final Programme 7 EADO European Association of Dermato Oncology GENERAL INFORMATION

DISABLED ACCESS There is easy access to and within the Megaron for guests with impaired mobility and the halls have specially designated areas for wheelchairs. Megaron was the recipient of a Helios Award (public buildings category) from the European Commission in recognition of its provision for the disabled.

LOST PROPERTY Enquiries regarding items lost or found can be made at the Registration Desk.

LUNCHES AND REFRESHMENTS Coffee/tea and lunch will be served in the exhibition area, apart from lunches on Thursday and Friday which will be served on the Foyer of the Banquet Hall.

MOBILE TELEPHONES Out of courtesy to speakers and other delegates, please switch mobile phones to silent mode when entering the Congress Halls.

SECURITY Any security problems or concerns should be reported to a uniformed member of staff.

SMOKING AREAS There are designated smoking areas in the Atrium of the Muses and outside the building at the Vas. Sofias street entrances.

VENUE LOCATION & TRANSPORT MAICC is situated right in the heart of Athens and is easily accessible by metro, bus and trolley bus. It is also located at a walking distance from major and smaller hotels. Commuting to and from the city centre and the Athens International Airport or other locations is quite easy: 30 min. from the Athens International Airport, 3-5 min. from the city centre. } For more information about MAICC please visit: www.maicc.gr

By Metro: There is direct access from the airport and the city centre to MAICC from the metro station “Megaron Moussikis” on metro line 3 (blue line). } Please visit the Athens Metro website for detailed information at www.ametro.gr

By Bus: The following buses, express buses and trolley buses pass and stop near the MAICC: • Buses: 450, 550, 601, 603 • Express Buses: X95 (direct airport line), A5, E6, E7, X14 • Cable “Trolley” Buses: 3, 7, 8, 13 } For more information about the public transportation network in Athens please visit: www.oasa.gr

6 13th Congress of the EADO • Athens, Greece Final Programme 7 From the airport: Athens International Airport “Eleftherios Venizelos” is located in Spata, 33 km southeast of Athens and serves all international and domestic flights. The airport is easily accessible from MAICC and the city centre via motorway, express bus or metro. An average journey by taxi from the airport to the city centre should take approximately 40-50 minutes, depending on traffic. The express bus line X95 (direction Syntagma) serves Athens city centre. A ticket for the airport express line costs €6. It allows unlimited travel by all public transport means (incl. bus and metro) for 24 hours from the time of validation. The metro line 3 runs every 30 minutes from the airport and the trip to the city centre takes approximately 30 minutes and costs €10. } For more information about the Athens International Airport please visit: www.aia.gr

SOCIAL PROGRAMME

OPENING CEREMONY Wednesday, May 3, 2017 18:15-18:30 hrs Dress code: Smart / casual The Opening Ceremony will take place in the “Banquet” Hall of the Congress Venue.

WELCOME RECEPTION Wednesday, May 3, 2017 19:00 hrs Dress code: Smart / casual An informal Welcome Reception will be held in the exhibition foyer of the Congress Venue for all delegates.

CONGRESS CLOSURE Saturday, May 6, 2017 13:45 hrs The Congress Closure will take place in the “Banquet” Hall of the Congress Venue.

8 13th Congress of the EADO • Athens, Greece Final Programme 9 EADO European Association of Dermato Oncology SCIENTIFIC INFORMATION

SPEAKERS’ PREVIEW ROOM The Speaker Preview facilities are located in a special designated area at the N. Skalkotas level (-1) in MC 3.3 room. All speakers should report there at their earliest convenience and no later than two hours before their presentation time, even if they are not using any audio-visual material. The Speaker Preview facilities will be operating according to the following schedule: Wednesday, May 3, 2017 12:00-18:00 Thursday, May 4, 2017 07:00-19:30 Friday, May 5, 2017 07:00-18:30 Saturday, May 6, 2017 07:30-13:00

ABSTRACTS All accepted abstracts (speakers presentations, free communications and e-posters) will be included in an electronic supplement of the JEADV Journal (available from June 30th, 2017). Editor-in-Chief: Prof. Johannes Ring Publisher: Wiley Website: http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1468-3083 A USB stick containing all abstracts will also be available in all delegate’s bags.

ACCREDITATION The European Association of Dermato Oncology (EADO) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The 13th Congress of the EADO is designated for a maximum of 18 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. ECMECs are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert ECMECs to AMA PRA category 1 credit, please contact the AMA.

ELECTRONIC POSTERS (E-POSTERS) All posters will be on display for the entire Congress and will be available for viewing during programme hours. The posters will be viewed on computers within a dedicated Poster Viewing Zone at the foyer of the Banquet Hall (level -2). E-posters are presented in two ways: on a large number of computers where every participant can search and view any poster, anytime during the Congress, and also on large 55-inch, high-definition monitors, with time-tabled schedule. A technician

8 13th Congress of the EADO • Athens, Greece Final Programme 9 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

will be available in the Poster area to help with any electronic poster queries. A list of all posters can be found on pages 43-58.

INSTRUCTIONS FOR BROWSING ELECTRONIC POSTERS AFTER THE CONGRESS Following the increasing trend for making scientific information available to the entire scientific community, the e-posters will be published online for one year, subject to the permission of their authors, at the following address: http://www.epostersonline.com/eado2017 All information, including the full text, as well as the full resolution PDF file of each poster will be searchable by poster title, author, institution, keywords or free text.

POSTER PRESENTATIONS AWARDS All poster presentations will be reviewed and evaluated by the Poster Awards Review Committee. The best three (3) poster presentations in the categories of clinical, experimental and translational research respectively, will each be awarded a price of Euro 500. The names of the winners will be announced during the Poster Awards Ceremony on Saturday, May 6, at 12:20 (Banquet Hall).

QUESTIONS TO SPEAKERS Wireless microphones will be at your disposal during the discussion period in all sessions. Delegates wishing to participate in the discussion periods should raise their hand and wait to be acknowledged by the chairperson.

CERTIFICATE OF ATTENDANCE An official Certificate of Attendance will be provided to all registered participants.

LANGUAGE The official language of the Congress is English. No simultaneous translation will be provided.

MOBILE APPLICATION The Scientific Programme is available for viewing through the mobile application. Delegates may scan the QR Code available here using their iPhone or Android. The scientificcontent will be evaluated through the mobile application; delegates are kindly requested to provide their feedback of the presentations they are attending.

10 13th Congress of the EADO • Athens, Greece Final Programme 11 10 13 13 th Congress of theEADO of Congress • Athens, Greece

PROGRAMMEOVERVIEW WEDNESDAY, MAY3,2017 SYMPOSIUM

WEDNESDAY 17:30-18:00 15:30-16:00 15:00-15:30 16:00-17:30 18:30-19:00 18:15-18:30 14:30-15:00 13:00-14:30 SY MAY 3 19:00 Time DERMOSCOPY COURSE DC THURSDAY MAY 4 Melanoma andNMSC: New developments– OPENING CEREMONY INDUSTRY SATELLITE OPENING KEYNOTE Melanoma: New developments – Open questions Open questions INDUSTRY SATELLITE SYMPOSIUM 2 SYMPOSIUM 1 Banquet Hall LECTURE 2 LECTURE LECTURE SL MAY 5 FRIDAY COFFEE BREAK–ePOSTERSVIEWING

INDUSTRY SATELLITE SYMPOSIUM SATURDAY SS MAY 6 WELCOME RECEPTION INDUSTRY SATELLITE INDUSTRY SATELLITE N. SkalkotasHall DERMOSCOPY DERMOSCOPY WORKSHOP LECTURE 1 LECTURE 3 COURSE 1 COURSE 2 W KEYNOTE LECTURE

KL INDUSTRY SATELLITE Prevention andskin cancer screening SYMPOSIUM WORKSHOP 1 Final Programme MC2 Hall EADO D E uropean ermato 1 O A ncology ssociation of

11

WEDNESDAY, MAY 3, 2017 12 WEDNESDAY, MAY 3, 2017 13:00-14:30 13:00-14:30 13:00-13:15 13:00-13:15 14:15-14:30 14:00-14:15 13:45-14:00 13:30-13:45 13:15-13:30 14:15-14:30 14:00-14:15 13:45-14:00 13:30-13:45 13:15-13:30 13 th Congress of theEADO of Congress

    DC1.5 DC1.4 DC1.3 DC1.2 DC1.1 In collaborationwiththeInternationalSocietyofDermoscopy C Melanoma: Newdevelopments–Openquestions SYMPOSIUM 1 C DERMOSCOPY COURSE1   SY1.5 SY1.4 SY1.3 SY1.2 SY1.1 hairs hairs : :

Aimilios Lallas(Thessaloniki,Greece) Iris Zalaudek(Graz,Austria) Austria) Christoph Hoeller(Vienna, Claus Garbe(Tuebingen, Germany) Discussion Paul Lorigan(Manchester, UnitedKingdom) Update onmucosalanduvealmelanoma Veronica Kinsler(London,UnitedKingdom) in treatment Melanoma arisingfrom congenitalnevi:Newdevelopments Georgina Long(Sydney treatment forBRAF-mutantmelanoma Choice ofimmunotherapyversustargeted therapyinfirstline Dirk Schadendorf(Essen,Germany) How longcheckpointinhibition–Untilobjectiveresponse? Austria) Christoph Hoeller(Vienna, PD-1 andCTLA-4:Upfront orsequentially? Discussion Dimitrios Sgouros (Athens,Greece) The spectrumofkeratinocyte skincancer Aimilios Lallas(Thessaloniki,Greece) The morphologicuniverse ofbasalcellcarcinoma Caterina Longo(Modena,Italy) Benign non-melanocyticlesions Josep Malvehy(Barcelona, Spain) Dermoscopic overviewofmelanoma Iris Zalaudek(Graz,Austria) Dermoscopy andtheevolutionofmelanocyticnevi • Athens, Greece

, Australia) WEDNESDAY, MAY3,2017 N. SKALKOTAS HALL

BANQUET HALL DC.1 SY.1 WEDNESDAY MAY 3 THURSDAY MAY 4 MAY 5 FRIDAY SATURDAY MAY 6 Final Programme EADO D E uropean ermato O A ncology ssociation of 13

12 13 th Congress of theEADO of Congress • Athens, Greece 16:00-17:30 15:30-16:00 14:30-15:30 14:30-15:00 16:00-16:15 16:30-16:45 16:15-16:30 17:15-17:30 17:00-17:15 16:45-17:00 WEDNESDAY MAY 3

 COFFEE BREAK–ePOSTERSVIEWING      THURSDAY Sponsored Session(seepage77) Sponsored Session(seepage77) C Open questions Melanoma andNMSC:Newdevelopments– SYMPOSIUM 2 INDUSTRY SATELLITE SYMPOSIUM 1 INDUSTRY SATELLITE LECTURE1    SY2.5 SY2.4 SY2.3 SY2.2 SY2.1 MAY 4 hairs :  Brigitte Dréno (Nantes,France) Vaccines andadoptiveT-cell transfer Axel Hauschild(Kiel,Germany) Targeted therapyinNRAS-mutatedmelanoma Discussion Jürgen Becker(Essen,Germany) C-Kit inhibitorsforacralmelanoma Ralf Gutzmer(Hannover, Germany) Targeted therapyand immunotherapy inadvancedSCC Celeste Lebbe(Paris,France) Immunotherapy inMerkelcellcarcinoma Hubert Pehamberger Austria) (Vienna, Jean-Jacques Grob MAY 5 FRIDAY

SATURDAY MAY 6 (Marseille, France)

N. SKALKOTAS HALL BANQUET HALL Final Programme MC2 HALL EADO D E SS.1 SY.2 SL.1 uropean ermato O A ncology ssociation of 13

WEDNESDAY, MAY 3, 2017 14 WEDNESDAY, MAY 3, 2017 16:00-17:30 16:00-17:30 16:00-16:15 16:00-16:15 17:15-17:30 17:00-17:15 16:45-17:00 16:30-16:45 16:15-16:30 17:15-17:30 17:00-17:15 16:45-17:00 16:30-16:45 16:15-16:30 13 th Congress of theEADO of Congress

    DC2.5 DC2.4 DC2.3 DC2.2 DC2.1 In collaborationwiththeInternationalSocietyofDermoscopy C DERMOSCOPY COURSE2 C Prevention andskincancer screening WORKSHOP 1   W1.6 W1.5 W1.4 W1.3 W1.2 W1.1 hairs hairs : :

Dorothea Polydorou (Athens,Greece) Ana-Maria Forsea(Bucharest, Romania) Alan Geller(Boston,USA) Georgios Chaidemenos (Thessaloniki, Greece) Austria) Harald Kittler(Vienna, Discussion Susana Puig(Barcelona, Spain) Dermoscopy andmolecularbiology Alexander Katoulis(Athens,Greece) Spitzoid lesions Rodica Cosgarea (Cluj-Napoca,Romania) Acral pigmentedlesions Elizabeth Lazaridou(Thessaloniki,Greece) Facial pigmentedlesions Austria) Harald Kittler(Vienna, skin tumours Clues fordiagnosingnon-andhypo-pigmentedmalignant Alan Geller(Boston,USA) Melanoma and skincancerscreening: What isthefuture? Véronique (Brussels,Belgium) delMarmol Challenges andsuccesses Screening andprevention ofmelanomainEurope: A Skin cancerscreening intheUnitedStates Peter Mohr(Buxtehude,Germany) Lessons from theGermanskincancerscreening programme Ana-Maria Forsea(Bucharest, Romania) Current standards inskincancerscreening Garbe(Tuebingen,Claus Germany) Does primaryprevention ofskincancerworkanywhere intheworld? • Athens, Greece rthur J.Sober(Boston,USA)

WEDNESDAY, MAY3,2017

N. SKALKOTAS HALL MC2 HALL DC.2 W.1

WEDNESDAY MAY 3 THURSDAY MAY 4 MAY 5 FRIDAY SATURDAY MAY 6 Final Programme EADO D E uropean ermato O A ncology ssociation of 15

14 13 th Congress of theEADO of Congress • Athens, Greece 18:30-19:00 18:15-18:30 17:30-18:00 17:30-18:00 19:00 WEDNESDAY MAY 3

WELCOME RECEPTION  OPENING CEREMONY   Boris Bastian(SanFrancisco,USA) The evolutionfrom melanocytestomelanoma Sponsored Session(seepage78) Sponsored Session(seepage77) C OPENING KEYNOTELECTURE INDUSTRY SATELLITE LECTURE3 INDUSTRY SATELLITE LECTURE2    THURSDAY MAY 4 hairs :

Claus Garbe(Tuebingen, Germany) Alexander J.Stratigos(Athens,Greece) MAY 5 FRIDAY SATURDAY MAY 6

N. SKALKOTAS HALL EXHIBITION AREA BANQUET HALL BANQUET HALL BANQUET HALL Final Programme EADO D E uropean ermato SL.2 SL.3 KL O A ncology ssociation of 15

WEDNESDAY, MAY 3, 2017 THURSDAY, MAY 4, 2017

PROGRAMME OVERVIEW

Time Banquet Hall N. Skalkotas Hall MC2 Hall

SYMPOSIUM 3 SYMPOSIUM 4 08:00-09:30 Epidemiology of Actinic keratoses - melanoma Field cancerisation WEDNESDAY, MAY 3, 2017 09:30-10:00 COFFEE BREAK – ePOSTERS VIEWING

SYMPOSIUM 6 SYMPOSIUM 5 10:00-11:30 Diagnostic aspects - Genetics of melanoma Pathology of melanoma

11:30-12:30 PLENARY LECTURES 1

INDUSTRY SATELLITE 12:45-13:45 LUNCH LUNCH BREAK SYMPOSIUM 2

FREE COMMUNICATIONS 1 Non-melanoma skin SYMPOSIUM 7 SYMPOSIUM 8 14:00-15:30 cancer: Merkel cell Surgery of melanoma Melanocytic nevi carcinoma, CTCL, rare skin tumours

INDUSTRY SATELLITE 15:30-16:30 SYMPOSIUM 3

16:30-17:00 COFFEE BREAK – ePOSTERS VIEWING

FREE COMMUNICATIONS 2 SYMPOSIUM 9 SYMPOSIUM 10 Topics in 17:00-18:30 Adjuvant therapy in Melanoma in difficult Dermato-oncology melanoma situations Late breaking abstracts SPECIAL SESSION Innovative pathways for INDUSTRY SATELLITE 18:30-19:30 innovative treatments SYMPOSIUM 4 in metastatic melanoma

SY PL SS FC SPS

SYMPOSIUM PLENARY LECTURE INDUSTRY SATELLITE FREE SPECIAL SESSION SYMPOSIUM COMMUNICATIONS

16 13th Congress of the EADO • Athens, Greece Final Programme 17 THURSDAY, MAY 4, 2017 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

THURSDAY, MAY 4, 2017

BANQUET HALL 08:00-09:30   SYMPOSIUM 3 Epidemiology of melanoma Time Banquet Hall N. Skalkotas Hall MC2 Hall Chairs: Véronique del Marmol (Brussels, Belgium) SY.3 Sara Gandini (Milan, Italy) SYMPOSIUM 3 SYMPOSIUM 4 Evangelos Evangelou (Ioannina, Greece) 08:00-09:30 Epidemiology of Actinic keratoses - melanoma Field cancerisation 08:00-08:15 SY3.1 Epidemiologic trends of melanoma 1950-2017 Eduardo Nagore (Valencia, Spain) 09:30-10:00 COFFEE BREAK – ePOSTERS VIEWING 08:15-08:30 SY3.2 Novel risk associations of melanoma Véronique del Marmol (Brussels, Belgium) SYMPOSIUM 6 SYMPOSIUM 5 10:00-11:30 Diagnostic aspects - Genetics of melanoma 08:30-08:45 SY3.3 Fast growing melanomas: Do they exist? Pathology of melanoma Jean-Jacques Grob (Marseille, France)

11:30-12:30 PLENARY LECTURES 1 08:45-09:00 SY3.4 Vitamin D and melanoma – An open controversy? Sara Gandini (Milan, Italy) INDUSTRY SATELLITE 09:00-09:15 SY3.5 The pathways to cutaneous melanoma 12:45-13:45 LUNCH LUNCH BREAK David Whiteman (Brisbane, Australia)

SYMPOSIUM 2 THURSDAY, MAY 4, 2017 09:15-09:30 Discussion FREE COMMUNICATIONS 1 Non-melanoma skin SYMPOSIUM 7 SYMPOSIUM 8 14:00-15:30 cancer: Merkel cell N. SKALKOTAS HALL Surgery of melanoma Melanocytic nevi carcinoma, CTCL, rare 08:00-09:30   SYMPOSIUM 4 skin tumours Actinic keratoses - Field cancerisation Chairs: Thomas Dirschka (Wuppertal, Germany) INDUSTRY SATELLITE SY.4 15:30-16:30 Demetrios Ioannides (Thessaloniki, Greece) SYMPOSIUM 3

08:00-08:15 SY4.1 Epidemiology and biology of actinic keratoses 16:30-17:00 COFFEE BREAK – ePOSTERS VIEWING Myrto Trakatelli (Brussels, Belgium) FREE COMMUNICATIONS 2 08:15-08:30 Do we need a new classification of actinic keratoses? SYMPOSIUM 9 SYMPOSIUM 10 SY4.2 Topics in Thomas Dirschka (Wuppertal, Germany) 17:00-18:30 Adjuvant therapy in Melanoma in difficult Dermato-oncology melanoma situations 08:30-08:45 Imaging of AK and field cancerisation Late breaking abstracts SY4.3 Caterina Longo (Modena, Italy) SPECIAL SESSION 08:45-09:00 SY4.4 Topical therapy for actinic keratoses: An update Innovative pathways for INDUSTRY SATELLITE 18:30-19:30 Girish Gupta (Airdrie, United Kingdom) innovative treatments SYMPOSIUM 4 in metastatic melanoma 09:00-09:15 SY4.5 PDT for actinic keratoses: Daylight versus conventional? Elena Sotiriou (Thessaloniki, Greece) 09:15-09:30 Discussion

09:30-10:00 COFFEE BREAK – ePOSTERS VIEWING

16 13th Congress of the EADO • Athens, Greece Final Programme 17 THURSDAY, MAY 4, 2017

BANQUET HALL 10:00-11:30   SYMPOSIUM 5 Genetics of melanoma Chairs: Julia Newton-Bishop (Leeds, United Kingdom) SY.5 Nicholas Hayward (Brisbane, Australia) Irene Stefanaki (Athens, Greece)

10:00-10:15 SY5.1 Novel high risk genes of melanoma Nicholas Hayward (Brisbane, Australia)

10:15-10:30 SY5.2 Genetic markers of prognostic outcome Efthymia Soura (Athens, Greece)

10:30-10:45 SY5.3 Genetic testing in daily clinical practice Susana Puig (Barcelona, Spain)

10:45-11:00 SY5.4 Using primary tumor transcriptomics to understand melanoma progression Julia Newton-Bishop (Leeds, United Kingdom)

11:00-11:15 SY5.5 Update on melanoma and UV-carcinogenesis

THURSDAY, MAY 4, 2017 Amaya Virós (Manchester, United Kingdom) 11:15-11:30 Discussion

N. SKALKOTAS HALL 10:00-11:30   SYMPOSIUM 6 Diagnostic aspects - Pathology of melanoma Chairs: Boris Bastian (San Francisco, USA) SY.6 Richard A. Scolyer (Sydney, Australia) Ioanna Lefaki (Thessaloniki, Greece)

10:00-10:15 SY6.1 Molecular classification of melanoma Boris Bastian (San Francisco, USA)

10:15-10:30 SY6.2 Is pathology the gold standard for diagnosing melanocytic tumours: Does it always glitter? Richard A. Scolyer (Sydney, Australia)

10:30-10:45 SY6.3 Regression in melanoma: From diagnosis to prognosis Simone Ribero (Turin, Italy)

10:45-11:00 SY6.4 Tumour infiltrating cells in melanoma Konstantina Frangia-Tsivou (Athens, Greece)

11:00-11:15 SY6.5 Molecular testing in melanoma – When, how and which test? Samuel Murray (Athens, Greece) 11:15-11:30 Discussion

18 13th Congress of the EADO • Athens, Greece Final Programme 19 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

BANQUET HALL 11:30-12:30   PLENARY LECTURES 1 Chairs: Hubert Pehamberger (Vienna, Austria) Axel Hauschild (Kiel, Germany) PL.1 Electra Nicolaidou (Athens, Greece)

11:30-11:50 PL1.1 Pathways of melanoma development: Prevention and therapeutic implications David E. Fisher (Boston, USA)

11:50-12:10 PL1.2 The epidemiology of melanoma: Recent changes and future challenges David Whiteman (Brisbane, Australia)

12:10-12:30 PL1.3 New imaging approaches for the diagnosis of melanoma and skin cancer Josep Malvehy (Barcelona, Spain)

BANQUET HALL

12:45-13:45  INDUSTRY SATELLITE LUNCH SYMPOSIUM 2 THURSDAY, MAY 4, 2017 Sponsored Session (see page 78) SS.2

BANQUET HALL 14:00-15:30   SYMPOSIUM 7 Surgery of melanoma Chairs: Vernon K. Sondak (Tampa, USA) SY.7 Roland Kaufmann (Frankfurt, Germany) Grigorios Champsas (Athens, Greece)

14:00-14:15 SY7.1 Current standards of surgical management in primary melanoma Roland Kaufmann (Frankfurt, Germany)

14:15-14:30 SY7.2 Evidence-based assessment of SLN in primary melanoma Alessandro Testori (Milan, Italy)

14:30-14:45 SY7.3 Lymph node surgery in patients with advanced disease Vernon K. Sondak (Tampa, USA)

14:45-15:00 SY7.4 Surgery of distant metastatic disease Vernon K. Sondak (Tampa, USA)

15:00-15:15 SY7.5 SLN beyond melanoma: Clinical application in skin cancers other than melanoma Jeffrey E. Gershenwald (Houston, USA) 15:15-15:30 Discussion

18 13th Congress of the EADO • Athens, Greece Final Programme 19 THURSDAY, MAY 4, 2017

N. SKALKOTAS HALL 14:00-15:30   SYMPOSIUM 8 Melanocytic nevi Chairs: Veronique Bataille (Hemel Hempstead, United Kingdom) SY.8 Harald Kittler (Vienna, Austria) Sophia Georgiou (Patras, Greece)

14:00-14:15 SY8.1 Genetics of melanocytic nevi Veronique Bataille (Hemel Hempstead, United Kingdom)

14:15-14:30 SY8.2 Classification of melanocytic nevi Harald Kittler (Vienna, Austria)

14:30-14:45 SY8.3 An update on CMM management Veronica Kinsler (London, United Kingdom)

14:45-15:00 SY8.4 Dysplastic nevus Iris Zalaudek (Graz, Austria)

15:00-15:15 SY8.5 Nevi monitoring: What’s new?

THURSDAY, MAY 4, 2017 Irene Stefanaki (Athens, Greece)

15:15-15:30 Discussion

MC2 HALL 14:00-15:30   FREE COMMUNICATIONS 1 Non-melanoma skin cancer: Merkel cell carcinoma, Cutaneous T-cell lymphoma, rare skin tumours FC.1 Chairs: Ana-Maria Forsea (Bucharest, Romania) Ricardo Vieira (Coimbra, Portugal)

14:00-14:08 FC1.1 The transgenic HPV8 mouse skin is associated with Lrig1 keratinocyte stem cell expansion Girish Patel (Cardiff, United Kingdom)

14:10-14:18 FC1.2 The polycomb proteins RING1B and EZH2 repress the tumoral proinflammatory function in metastatic cutaneous squamous cell carcinoma Agusti Toll (Barcelona, Spain)

14:20-14:28 FC1.3 Merkel cell carcinomas are RESTless Axel zur Hausen (Maastricht, The Netherlands)

14:30-14:38 FC1.4 Treatment and survival of 351 patients with Merkel cell carcinoma in 2 expert-centres Linde van Veenendaal (Amsterdam, The Netherlands)

20 13th Congress of the EADO • Athens, Greece Final Programme 21 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

14:40-14:48 FC1.5 Cutaneous mosaic syndromes associated with early postzygotic activating BRAF mutations Pierre Vabres (Dijon, France)

14:50-14:58 FC1.6 The value of genetic testing in patients with basal cell nevus syndrome: A multicenter retrospective cohort study Betül Cosgun (Maastricht, The Netherlands)

15:00-15:08 FC1.7 The heterogenous immune landscape of mycosis fungoides Duncan Murray (Birmingham, United Kingdom)

15:10-15:18 FC1.8 Interferon alpha remains an effective treatment for early stage refractory mycosis fungoides (MF), advanced MF and Sezary Syndrome Marianne de Brito (Birmingham, United Kingdom)

15:20-15:28 FC1.9 Prospective pilot study evaluating the effectiveness of electrochemotherapy using reduced dosages of intravenous bleomycin Simone Ribero (Turin, Italy)

BANQUET HALL

15:30-16:30  INDUSTRY SATELLITE SYMPOSIUM 3 THURSDAY, MAY 4, 2017 Sponsored Session (see page 78) SS.3

16:30-17:00 COFFEE BREAK – ePOSTERS VIEWING

BANQUET HALL 17:00-18:30   SYMPOSIUM 9 Adjuvant therapy in melanoma Chairs: Alexander M.M. Eggermont (Paris, France) SY.9 Helen Gogas (Athens, Greece)

17:00-17:15 SY9.1 Updates in adjuvant melanoma trials Helen Gogas (Athens, Greece)

17:15-17:30 SY9.2 Ipilimumab as an adjuvant approach to high risk melanoma Alexander M.M. Eggermont (Paris, France)

17:30-17:45 SY9.3 Anti- PD1 antibodies in the adjuvant setting Brigitte Dréno (Nantes, France)

17:45-18:00 SY9.4 Kinase inhibitors in the adjuvant setting Axel Hauschild (Kiel, Germany)

18:00-18:15 SY9.5 2017 State of the art for adjuvant therapy in melanoma: Concluding remarks Helen Gogas (Athens, Greece) 18:15-18:30 Discussion

20 13th Congress of the EADO • Athens, Greece Final Programme 21 THURSDAY, MAY 4, 2017

N. SKALKOTAS HALL 17:00-18:30   SYMPOSIUM 10 Melanoma in difficult situations Chairs: Petr Arenberger (Prague, Czech Republic) SY.10 Lidija Kandolf-Sekulovic (Belgrade, Serbia) Dimitrios Rigopoulos (Athens, Greece)

17:00-17:15 SY10.1 Melanoma and pregnancy Zoe Apalla (Thessaloniki, Greece)

17:15-17:30 SY10.2 Melanoma arising in childhood Christina Stefanaki (Athens, Greece)

17:30-17:45 SY10.3 Current need of early diagnosis in metastatic melanoma Petr Arenberger (Prague, Czech Republic)

17:45-18:00 SY10.4 Melanoma of the nail unit Dimitrios Rigopoulos (Athens, Greece)

18:00-18:15 SY10.5 Melanoma in the immunosuppressed patient Catherine Harwood (London, United Kingdom) THURSDAY, MAY 4, 2017 18:15-18:30 Discussion

MC2 HALL 17:00-18:30   FREE COMMUNICATIONS 2 Topics in Dermato-oncology | Late breaking abstracts Chairs: Reinhard Dummer (Zürich, Switzerland) FC.2 Eduardo Nagore (Valencia, Spain)

17:00-17:08 FC2.1 Tumor-stroma based prognosis in primary cutaneous melanoma: Validation and exploratory analysis of an eight-gene risk score Thomas Dirschka (Wuppental, Germany)

17:10-17:18 FC2.2 Clinical characteristics associated with Spitz nevi, atypical Spitz nevi and melanomas in patients younger than 20 years: A 15-year retrospective study from “Andreas Sygros” Hospital (2004 to 2016) Efthymia Soura (Athens, Greece)

17:20-17:28 FC2.3 The insidence of false negative sentinel lymph node biopsy in melanoma and its impact on the treatment of the disease Parthena Deskoulidi (Athens, Greece)

17:30-17:38 FC2.4 Sonidegib’s duration of response: Results from the pivotal phase 2 BOLT study over 30 months in patients with locally advanced basal cell carcinoma Michael Migden (Houston, USA)

22 13th Congress of the EADO • Athens, Greece Final Programme 23 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

17:40-17:48 FC2.5 Routine management of adverse effects during treatment with the hedgehog inhibitor Vismodegib: A single center experience Iris Zalaudek (Graz, Austria)

17:50-17:58 FC2.6 Relationship between talimogene laherparepvec and intratumoural CD8+ density in patients with unresectable stage IIIB-IVM1c melanoma: Interim efficacy, safety and biomarker results of a Phase 2 study Josep Malvehy (Barcelona, Spain)

18:00-18:08 FC2.7 Evaluation of melanocitic tumours in chronic graft versus host disease patients. A clinical challenge for dermatologist Alicia Barreiro-Capurro (Barcelona, Spain)

18:10-18:18 FC2.8 Sarcoid-like reactions under modern melanoma treatment Florentia Dimitriou (Zurich, Switzerland)

BANQUET HALL 18:30-19:30   SPECIAL SESSION 1

Innovative pathways for innovative treatments in THURSDAY, MAY 4, 2017 metastatic melanoma SPS Moderators: Claus Garbe (Tuebingen, Germany) Ana-Maria Forsea (Bucharest, Romania) Lidija Kandolf-Sekulovic (Belgrade, Serbia)

18:30-18:40 SS1.1 Access to innovative medicines in Europe: An overview Lidija Kandolf-Sekulovic (Belgrade, Serbia)

18:40-18:50 SS1.2 ESMO EU Policy Committee initiatives for improved access to innovative medicines Rosa Giuliani (Rome, Italy)

18:50-19:00 SS1.3 Melanoma Patient Network Europe initiatives for improved access to innovative medicines Bettina Ryll (Uppsala, Sweden)

19:00-19:10 SS1.4 EFPIA initiatives for improved access to innovative medicines Alexander Roediger (Kriens, Switzerland)

19:10-19:30 Panel discussion (all speakers)

N. SKALKOTAS HALL

18:30-19:30  INDUSTRY SATELLITE SYMPOSIUM 4 Sponsored Session (see page 79) SS.4

22 13th Congress of the EADO • Athens, Greece Final Programme 23 FRIDAY, MAY 5, 2017 FRIDAY, MAY 5, 2017 PROGRAMME OVERVIEW

Time Banquet Hall N. Skalkotas Hall MC2 Hall

SYMPOSIUM 12 SYMPOSIUM 11 FREE COMMUNICATIONS 3 Cutaneous adverse Treatment approaches Non-melanoma skin 08:00-09:30 reactions to for advanced stage cancer: Basal cell and chemotherapy and BCC and SCC squamous cell carcinoma targeted therapies

09:30-10:00 COFFEE BREAK – ePOSTERS VIEWING

SYMPOSIUM 13 SYMPOSIUM 14 SYMPOSIUM 15 10:00-11:30 Targeted therapy of Regional drug therapies Melanoma genetics advanced melanoma in melanoma and NMSC and biology

11:30-12:30 PLENARY LECTURES 2

INDUSTRY SATELLITE 12:45-13:45 LUNCH BREAK LUNCH SYMPOSIUM 5

SYMPOSIUM 16 SYMPOSIUM 17 Immunotherapy of Predictive biomarkers FREE COMMUNICATIONS 4 14:00-15:30 advanced melanoma: and disease monitoring Melanoma Beyond CTLA4 and PD-1 in melanoma

INDUSTRY SATELLITE 15:30-16:30

FRIDAY, MAY 5, 2017 SYMPOSIUM 6

16:30-17:00 COFFEE BREAK – ePOSTERS VIEWING

SYMPOSIUM 18 SURGICAL WORKSHOP 2 Combination treatments SYMPOSIUM 19 Surgical approach of 17:00-18:30 and treatment algorithms Brain metastases melanoma - Its role in metastatic melanoma from stage I to IV

SY FC PL SS W

SYMPOSIUM FREE PLENARY LECTURE INDUSTRY SATELLITE WORKSHOP COMMUNICATIONS SYMPOSIUM

24 13th Congress of the EADO • Athens, Greece Final Programme 25 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO FRIDAY, MAY 5, 2017 European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

FRIDAY, MAY 5, 2017 BANQUET HALL 08:00-09:30   SYMPOSIUM 11 Time Banquet Hall N. Skalkotas Hall MC2 Hall Treatment approaches for advanced stage BCC and SCC Chairs: Alexander J. Stratigos (Athens, Greece) SY.11 SYMPOSIUM 12 SYMPOSIUM 11 FREE COMMUNICATIONS 3 Nicole Basset-Séguin (Paris, France) Cutaneous adverse Treatment approaches Non-melanoma skin Andreas Katsambas (Athens, Greece) 08:00-09:30 reactions to for advanced stage cancer: Basal cell and chemotherapy and 08:00-08:15 SY11.1 Update on systemic treatment of basal cell carcinoma BCC and SCC squamous cell carcinoma targeted therapies Alexander J. Stratigos (Athens, Greece)

08:15-08:30 SY11.2 HPI resistance mechanisms and how to overcome it 09:30-10:00 COFFEE BREAK – ePOSTERS VIEWING Nicole Basset-Séguin (Paris, France)

08:30-08:45 SY11.3 Managing adverse reactions to HPI SYMPOSIUM 13 SYMPOSIUM 14 SYMPOSIUM 15 Clio Dessinioti (Athens, Greece) 10:00-11:30 Targeted therapy of Regional drug therapies Melanoma genetics advanced melanoma in melanoma and NMSC and biology 08:45-09:00 SY11.4 Checkpoint blockade in NMSC Dirk Schadendorf (Essen, Germany)

09:00-09:15 SY11.5 Systemic treatment of BCC: Beyond hedgehog pathway inhibitors 11:30-12:30 PLENARY LECTURES 2 Rainer Kunstfeld (Vienna, Austria) 09:15-09:30 Discussion INDUSTRY SATELLITE 12:45-13:45 LUNCH BREAK LUNCH SYMPOSIUM 5 N. SKALKOTAS HALL 08:00-09:30   SYMPOSIUM 12 SYMPOSIUM 16 SYMPOSIUM 17 Cutaneous adverse reactions to chemotherapy and Immunotherapy of Predictive biomarkers FREE COMMUNICATIONS 4 14:00-15:30 targeted therapies advanced melanoma: and disease monitoring Melanoma SY.12 Chairs: Celeste Lebbe (Paris, France) Beyond CTLA4 and PD-1 in melanoma Alexandra Katsarou (Athens, Greece) Panagiotis Stavropoulos (Athens, Greece) INDUSTRY SATELLITE 15:30-16:30

SYMPOSIUM 6 08:00-08:15 SY12.1 Classic cutaneous adverse reactions from chemotherapeutic agents FRIDAY, MAY 5, 2017 Aikaterini Patsatsi (Thessaloniki, Greece) 16:30-17:00 COFFEE BREAK – ePOSTERS VIEWING 08:15-08:30 SY12.2 Cutaneous reactions to anti-EGFR agents Celeste Lebbe (Paris, France) SYMPOSIUM 18 SURGICAL WORKSHOP 2 Combination treatments SYMPOSIUM 19 Surgical approach of 08:30-08:45 SY12.3 Cutaneous reactions to immune checkpoint inhibitors 17:00-18:30 and treatment algorithms Brain metastases melanoma - Its role Vincent Sibaud (Toulouse, France) in metastatic melanoma from stage I to IV 08:45-09:00 SY12.4 Cutaneous reactions to BRAF/MEK inhibitors and PI3K inhibitors Elisabeth Livingstone (Essen, Germany)

09:00-09:15 SY12.5 A therapeutic algorithm for managing adverse skin reactions to targeted oncologic therapies Ioanna Panoutsopoulou (Athens, Greece) 09:15-09:30 Discussion

24 13th Congress of the EADO • Athens, Greece Final Programme 25 FRIDAY, MAY 5, 2017

MC2 HALL 08:00-09:30   FREE COMMUNICATIONS 3 Non-melanoma skin cancer: Basal cell and squamous cell carcinoma FC.3 Chairs: Petr Arenberger (Prague, Czech Republic) John Paoli (Gothenburg, Sweden)

08:00-08:08 FC3.1 Health-Related Quality of Life (HRQoL) analysis by skindex-16 in MIKIE, long-term follow-up from the randomized, phase 2 study to assess the efficacy and safety of two intermittent vismodegib regimens in patients with multiple Basal Cell Carcinomas (BCCs) Dirk Schadendorf (Essen, Germany)

08:10-08:18 FC3.2 Long-term follow-up from MIKIE: A randomized, double-blind, phase 2 study to assess the efficacy and safety of two intermittent vismodegib regimens in patients with multiple Basal Cell Carcinomas (BCCs) Rainer Kunstfeld (Vienna, Austria)

08:20-08:28 FC3.3 Correlation between clinical and histological patterns in 2710 basal cell carcinomas: A French multicentric prospective study Lea Dousset (Bordeaux, France)

08:30-08:38 FC3.4 Comparison of long-term aesthetic outcomes for different treatments of superficial basal cell carcinoma Maud Jansen (Maastricht, The Netherlands)

08:40-08:48 FC3.5 Insights from RegiSONIC on the diagnosis and treatment of locally advanced basal cell carcinoma by type of practice Laura Chu (San Francisco, USA)

08:50-08:58 FC3.6 Retrospective chart review to characterize real-world patients with difficult-to-treat (dt) Basal Cell Carcinoma (BCC) who are potential FRIDAY, MAY 5, 2017 candidates for Hedgehog Pathway Inhibitors (HPIs) Jean-Jacques Grob (Marseille, France)

09:00-09:08 FC3.7 Recent developments in the management of patients with squamous cell skin carcinoma risk: The Greek 10-year experience in squamous cell carcinoma of two centers Emmanouil Dimonitsas (Athens, Greece)

09:10-09:18 FC3.8 Efficacy of ingenol mebutate compared to diclofenac for patients with actinic keratosis on the face or scalp Eggert Stockfleth (Bochum, Germany)

09:20-09:28 FC3.9 Safety of ingenol mebutate compared to diclofenac for patients with actinic keratosis on the face or scalp Eggert Stockfleth (Bochum, Germany)

26 13th Congress of the EADO • Athens, Greece Final Programme 27 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

09:30-10:00 COFFEE BREAK – ePOSTERS VIEWING

BANQUET HALL 10:00-11:30   SYMPOSIUM 13 Targeted therapy of advanced melanoma Chairs: Axel Hauschild (Kiel, Germany) SY.13 Georgina Long (Sydney, Australia) Dimitrios Bafaloukos (Athens, Greece)

10:00-10:15 SY13.1 Clinical update on approved targeted therapies in advanced melanoma Dirk Schadendorf (Essen, Germany)

10:15-10:30 SY13.2 Monitoring response to targeted therapies in advanced melanoma Christoph Hoeller (Vienna, Austria)

10:30-10:45 SY13.3 Resistance mechanisms to kinase inhibitors Caroline Robert (Paris, France)

10:45-11:00 SY13.4 New candidate therapeutic targets Reinhard Dummer (Zürich, Switzerland)

11:00-11:15 SY13.5 Managing adverse reactions to kinase inhibitors Helena Linardou (Athens, Greece) 11:15-11:30 Discussion

N. SKALKOTAS HALL 10:00-11:30   SYMPOSIUM 14 Regional drug therapies in melanoma and NMSC Chairs: Odysseas Zoras (Heraklion, Greece) SY.14 Alessandro Testori (Milan, Italy) Nikolaos Koliarakis (Athens, Greece) FRIDAY, MAY 5, 2017

10:00-10:15 SY14.1 Intralesional T-VEC and combination Sanjiv S. Agarwala (Bethlehem, USA)

10:15-10:30 SY14.2 Electrochemotherapy Alessandro Testori (Milan, Italy)

10:30-10:45 SY14.3 Isolated limb perfusion: Is it still an option? Odysseas Zoras (Heraklion, Greece)

10:45-11:00 SY14.4 Lesional chemotherapy and cytokines Natalia Rompoti (Athens, Greece)

11:00-11:15 SY14.5 Immunocryosurgery Georgios Gaitanis (Ioannina, Greece) 11:15-11:30 Discussion

26 13th Congress of the EADO • Athens, Greece Final Programme 27 FRIDAY, MAY 5, 2017

MC2 HALL 10:00-11:30   SYMPOSIUM 15 Melanoma genetics and biology Chairs: Maria-Teresa Landi (Bethesda, USA) Stefan Beissert (Dresden, Germany) SY.15 Theofanis Floros (Athens, Greece)

10:00-10:15 SY15.1 Polygenic risk score for cutaneous melanoma in Mediterranean countries Maria-Teresa Landi (Bethesda, USA)

10:15-10:30 SY15.2 UV-induced immunosuppression and melanoma development Stefan Beissert (Dresden, Germany)

10:30-10:45 SY15.3 Whole genome sequencing of major melanoma subtypes and its relevance for patient care Richard A. Scolyer (Sydney, Australia)

10:45-11:00 SY15.4 B-cells and antibody responses in melanoma: Immune escape mechanisms and opportunities for translation Sophia N. Karagiannis (London, United Kingdom)

11:00-11:15 SY15.5 Resistance to checkpoint inhibitors Theofanis Floros (Athens, Greece)

11:15-11:30 Discussion

BANQUET HALL 11:30-12:30   PLENARY LECTURES 2 Chairs: Helen Gogas (Athens, Greece) Alexander J. Stratigos (Athens, Greece) PL.2 FRIDAY, MAY 5, 2017

11:30-11:50 PL2.1 The new (8th edition) AJCC melanoma staging system Jeffrey E. Gershenwald (Houston, USA)

11:50-12:10 PL2.2 The evolving therapeutic landscape of advanced melanoma Georgina Long (Sydney, Australia)

12:10-12:30 PL2.3 Merkel cell carcinoma: New insights in biology and treatment Paul Nghiem (Seattle, USA)

BANQUET HALL

12:45-13:45  INDUSTRY SATELLITE LUNCH SYMPOSIUM 5 Sponsored Session (see page 79) SS.5

28 13th Congress of the EADO • Athens, Greece Final Programme 29 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

BANQUET HALL 14:00-15:30  SYMPOSIUM 16 Immunotherapy of advanced melanoma: Beyond CTLA4 and PD-1 Chairs: Dirk Schadendorf (Essen, Germany) Reinhard Dummer (Zürich, Switzerland) Aristotelis Bamias (Athens, Greece) SY.16

14:00-14:15 SY16.1 Update in anti-CTLA1 and anti-PD1 treatment in advanced melanoma Christian Blank (Amsterdam, The Netherlands)

14:15-14:30 SY16.2 Overcoming lack of response to checkpoint inhibitors Caroline Robert (Paris, France)

14:30-14:45 SY16.3 Optimising use of antigen-specific immunotherapy in advanced melanoma Ralf Gutzmer (Hannover, Germany)

14:45-15:00 SY16.4 Targeted therapy and immunotherapy in uveal melanoma Sanjiv S. Agarwala (Bethlehem, USA)

15:00-15:15 SY16.5 Open questions in immunotherapy Dimitrios Bafaloukos (Athens, Greece) 15:15-15:30 Discussion

N. SKALKOTAS HALL 14:00-15:30  SYMPOSIUM 17 Predictive biomarkers and disease monitoring in melanoma Chairs: Helen Gogas (Athens, Greece) Jürgen Becker (Essen, Germany) SY.17

14:00-14:15 SY17.1 How does our surveillance algorithm change with the new therapies? Olivier Michielin (Lausanne, Switzerland) FRIDAY, MAY 5, 2017

14:15-14:30 SY17.2 Serologic markers with predictive value Philippe Saiag (Paris, France)

14:30-14:45 SY17.3 Blood and tissue biomarkers of response to targeted therapy/ immunotherapy Jürgen Becker (Essen, Germany)

14:45-15:00 SY17.4 Circulating tumour cells in melanoma Evi S. Lianidou (Athens, Greece)

15:00-15:15 SY17.5 Update on imaging for disease monitoring Sofia Chatziioannou (Athens, Greece) 15:15-15:30 Discussion

28 13th Congress of the EADO • Athens, Greece Final Programme 29 FRIDAY, MAY 5, 2017

MC2 HALL 14:00-15:30   FREE COMMUNICATIONS 4 Melanoma hairs C : Christoph Hoeller (Vienna, Austria) FC.4 Helena Linardou (Athens, Greece)

14:00-14:08 FC4.1 Dermoscopy of melanoma in situ Chrysoula Papageorgiou (Thessaloniki, Greece)

14:10-14:18 FC4.2 In situ evaluation of markers of activation and inhibition of Tumor Infiltrating Lymphocytes (TILs) after microdissection: Remarks to the current morphologic classification of the “TILs patterns” Francesca Maria Bosisio (Leuven, Belgium)

14:20-14:28 FC4.3 Preliminary in vitro-data indicating a potential protumorigenic function for 4-1BBL+ melanoma subpopulations Panagiotis Kampilafkos (Duisburg, Germany)

14:30-14:38 FC4.4 Baseline neutrophil-lymphocyte ratio is associated with metastases of cutaneous melanoma to the sentinel lymph node Alyss V. Robinson (Leeds, United Kingdom)

14:40-14:48 FC4.5 Novel germline variants in cutaneous and uveal melanoma families Nicholas Hayward (Brisbane, Australia)

14:50-14:58 FC4.6 TRILOGY/IMspire150: A phase 3, double-blinded, randomized study of atezolizumab (A) plus cobimetinib (C) combined with vemurafenib (V) vs placebo plus C combined with V in previously untreated BRAFV600 mutation-positive patients with locally advanced or metastatic melanoma (NCT02908672/EudraCT 2016-002482-54) Paolo Ascierto (Naples, Italy)

15:00-15:08 FC4.7 Retrospective medical record review of melanoma patients

FRIDAY, MAY 5, 2017 with BMs treated with SRS or WBR in combination with immune checkpoint inhibitors (ICI) or BRAF +/- MEK inhibitors (BRAFi +/- MEKi) in the Departments of Radiation Oncology and Dermatooncology of the University Hospital Dresden from March 2014 to March 2016 Maria Chapsa (Dresden, Germany)

15:10-15:18 FC4.8 Association of depth of response with survival outcomes in prognostic groups of patients treated with cobimetinib (C) ± vemurafenib (V): A pooled analysis of the BRIM-2, -3, -7, and coBRIM studies Paolo Ascierto (Naples, Italy)

15:20-15:28 FC4.9 Evaluation of circulating microRNAs as diagnostic circulating biomarkers in cutaneous melanoma Beatrice Polini (Pisa, Italy)

30 13th Congress of the EADO • Athens, Greece Final Programme 31 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

MC2 HALL

15:30-16:30  INDUSTRY SATELLITE SYMPOSIUM 6 Sponsored Session (see page 79) SS.6

16:30-17:00 COFFEE BREAK – ePOSTERS VIEWING

BANQUET HALL 17:00-18:30   SYMPOSIUM 18 Combination treatments and treatment algorithms in metastatic melanoma Chairs: Christian Blank (Amsterdam, The Netherlands) SY.18 Caroline Robert (Paris, France)

17:00-17:15 SY18.1 Molecular testing for targeted therapies Claus Garbe (Tuebingen, Germany)

17:15-17:30 SY18.2 Combining checkpoint inhibitors Olivier Michielin (Lausanne, Switzerland)

17:30-17:45 SY18.3 Combining immune checkpoint and kinase inhibitors Paolo Ascierto (Naples, Italy)

17:45-18:00 SY18.4 Combination of systemic with intralesional therapies Reinhard Dummer (Zürich, Switzerland)

18:00-18:30 Discussion

N. SKALKOTAS HALL 17:00-18:30   SYMPOSIUM 19 Brain metastases Chairs: Friedegund Meier (Dresden, Germany) SY.19 Ilias Athanasiadis (Athens, Greece) FRIDAY, MAY 5, 2017

17:00-17:15 SY19.1 Brain metastases: Epidemiology and predisposing factors Apostolos Laskarakis (Athens, Greece)

17:15-17:30 SY19.2 Brain metastases: The targeted approach (kinase inhibitors, checkpoint inhibitors) Friedegund Meier (Dresden, Germany)

17:30-17:45 SY19.3 Brain metastases: Is their role of conventional chemotherapy? Peter Mohr (Buxtehude, Germany)

17:45-18:00 SY19.4 Brain metastases: Gamma knife and new treatments Jean-Jacques Grob (Marseille, France)

18:00-18:30 Discussion

30 13th Congress of the EADO • Athens, Greece Final Programme 31 FRIDAY, MAY 5, 2017

MC2 HALL 17:00-18:30   SURGICAL WORKSHOP 2 Surgical approach of melanoma - Its role from stage I to IV Chairs: Roland Kaufmann (Frankfurt, Germany) David Moreno-Ramírez (Seville, Spain) W.2 Petros Panayotou (Athens, Greece)

17:00-17:15 W2.1 Primary melanoma surgery John Paoli (Gothenburg, Sweden)

17:15-17:30 W2.2 Surgery of primary melanoma in difficult sites Roland Kaufmann (Frankfurt, Germany)

17:30-17:45 W2.3 Sentinel lymph node biopsy Alessandro Testori (Milan, Italy)

17:45-18:00 W2.4 Nodal surgery Dimosthenis Tsoutsos (Athens, Greece)

18:00-18:15 W2.5 Surgical treatment of in-transit and M1a disease David Moreno-Ramírez (Seville, Spain) 18:15-18:30 Discussion FRIDAY, MAY 5, 2017

32 13th Congress of the EADO • Athens, Greece Final Programme 33 SATURDAY,WEDNESDAY THURSDAY MAY 6,FRIDAY 2017 SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology PROGRAMME OVERVIEW

Time Banquet Hall N. Skalkotas Hall MC2 Hall

SYMPOSIUM 20 SYMPOSIUM 21 Treatment approaches Cutaneous lymphomas: 08:30-10:00 for early and advanced Epidemiology, diagnosis BCC and SCC and classification

10:00-10:30 COFFEE BREAK – ePOSTERS VIEWING

SYMPOSIUM 23 SYMPOSIUM 22 Cutaneous lymphomas: 10:30-12:00 Rare malignant skin Management and tumours treatment

CLOSING KEYNOTE LECTURE 12:00-12:20 Managing melanoma in 2017: Challenges and perspectives

POSTER AWARDS 12:20-12:30 CEREMONY

WORKSHOP 3 SYMPOSIUM 24 12:30-13:45 Dermoscopy: Dermatologic FRIDAY, MAY 5, 2017 Interactive cases surgery

13:45 CONGRESS CLOSURE

SY KL W

SYMPOSIUM KEYNOTE LECTURE WORKSHOP

32 13th Congress of the EADO • Athens, Greece Final Programme 33 SATURDAY, MAY 6, 2017

BANQUET HALL 08:30-10:00   SYMPOSIUM 20 Treatment approaches for early and advanced BCC and SCC Chairs: Irene M. Leigh (London, United Kingdom) Matilda Bylaitė-Bučinskienė (Vilnius, Lithuania) Ioannis Bassukas (Ioannina, Greece) SY.20

08:30-08:45 SY20.1 Updates on the biology and treatment of actinic keratosis Eggert Stockfleth (Bochum, Germany)

08:45-09:00 SY20.2 What is new in the biology of SCC? Irene M. Leigh (London, United Kingdom)

09:00-09:15 SY20.3 How to define high risk BCC and SCC? John Lear (Manchester, United Kingdom)

09:15-09:30 SY20.4 Topical therapies of NMSC Günther Hofbauer (Zürich, Switzerland)

09:30-09:45 SY20.5 Conventional and daylight PDT Rolf-Markus Szeimies (Recklinghausen, Germany)

09:45-10:00 SY20.6 Hedgehog inhibitors in advanced BCC Ketty Peris (Rome, Italy)

N. SKALKOTAS HALL 08:30-10:00   SYMPOSIUM 21 Cutaneous lymphomas: Epidemiology, diagnosis and classification SY.21 Chairs: Maarten H. Vermeer (Leiden, The Netherlands) Robert Knobler (Vienna, Austria) Dimitrios Sotiriadis (Thessaloniki, Greece)

08:30-08:45 SY21.1 Classification of cutaneous lymphomas: New aspects Pietro Quaglino (Torino, Italy)

08:45-09:00 SY21.2 Prognostic factors in mycosis fungoides Julia Scarisbrick (Birmingham, United Kingdom)

09:00-09:15 SY21.3 Diagnostic approach in CD30+ cutaneous lymphomas Maarten H. Vermeer (Leiden, The Netherlands)

09:15-09:30 SY21.4 Folliculotropic mycosis fungoides: An update Rein Willemze (Leiden, The Netherlands)

09:30-09:45 SY21.5 CD8+ lymphoid infiltrates Vasiliki Nikolaou (Athens, Greece) SATURDAY, MAY 6, 2017 09:45-10:00 Discussion

34 13th Congress of the EADO • Athens, Greece Final Programme 35 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

10:00-10:30 COFFEE BREAK – ePOSTERS VIEWING

BANQUET HALL 10:30-12:00   SYMPOSIUM 22 Rare malignant skin tumours Chairs: Philippe Saiag (Paris, France) SY.22 Judit Oláh (Szeged, Hungary) Vasiliki Chasapi (Athens, Greece)

10:30-10:45 SY22.1 Merkel cell carcinoma Konstantinos Krasagakis (Heraklion, Greece)

10:45-11:00 SY22.2 Dermatofibrosarcoma protuberans Philippe Saiag (Paris, France)

11:00-11:15 SY22.3 Cutaneous sarcomas Judit Oláh (Szeged, Hungary)

11:15-11:30 SY22.4 Adnexal malignant tumours Angeliki Befon (Athens, Greece)

11:30-11:45 SY22.5 Genodermatoses with predisposition to skin cancer Matilda Bylaitė-Bučinskienė (Vilnius, Lithuania) 11:45-12:00 Discussion

N. SKALKOTAS HALL 10:30-12:00   SYMPOSIUM 23 Cutaneous lymphomas: Management and treatment Chairs: Rudolf Stadler (Minden, Germany) SY.23 Christina Antoniou (Athens, Greece) Leonidas Marinos (Athens, Greece)

10:30-10:45 SY23.1 Treatment of early stage mycosis fungoides Evangelia Papadavid (Athens, Greece)

10:45-11:00 SY23.2 Treatment of late stage MF Rudolf Stadler (Minden, Germany)

11:00-11:15 SY23.3 Extracorporeal photopheresis in CTCL: Update 2017 Robert Knobler (Vienna, Austria)

11:15-11:30 SY23.4 Treatment of cutaneous B-cell lymphomas Marina Siakantaris (Athens, Greece)

11:30-11:45 SY23.5 New treatment for mycosis fungoides Pablo Ortiz-Romero (Madrid, Spain) SATURDAY, MAY 6, 2017 11:45-12:00 Discussion

34 13th Congress of the EADO • Athens, Greece Final Programme 35 SATURDAY, MAY 6, 2017

BANQUET HALL 12:00-12:20  CLOSING KEYNOTE LECTURE Managing melanoma in 2017: Challenges and perspectives Chairs: Alexander J. Stratigos (Athens, Greece) KL Nikolaos Stavrianeas (Athens, Greece) Challenges for Dermato-Oncology Claus Garbe (Tuebingen, Germany)

BANQUET HALL 12:20-12:30 POSTER AWARDS CEREMONY

BANQUET HALL 12:30-13:45  WORKSHOP 3 Dermoscopy: Interactive cases Chairs: Alexander J. Stratigos (Athens, Greece) W.3 Aimilios Lallas (Thessaloniki, Greece) EXPERTS PANEL: Harald Kittler (Vienna, Austria), Josep Malvehy (Barcelona, Spain), Susana Puig (Barcelona, Spain), Aimilios Lallas (Thessaloniki, Greece) CASE PRESENTERS: Zoe Apalla (Thessaloniki, Greece), George Evangelou (Heraklion, Greece), Dimitrios Sgouros (Athens, Greece), Dimitrios Papakostas (Athens, Greece), Fotini Chatzinasiou (Athens, Greece)

MC2 HALL 12:30-13:45  SYMPOSIUM 24 Dermatologic surgery - In collaboration with the Hellenic Society of Dermatologic Surgery Chairs: Dimitra Ntasiou (Volos, Greece) Philippe Saiag (Paris, France) Georgia Avgerinou (Athens, Greece) SY.24

12:30-12:45 SY24.1 An update on surgery and Mohs for NMSC Ricardo Vieira (Coimbra, Portugal)

12:45-13:00 SY24.2 Reconstructive surgery of special areas Dimitra Ntasiou (Volos, Greece)

13:00-13:15 SY24.3 Making surgical complications less complicated Athanasios Kalampokas (Athens, Greece)

13:15-13:30 SY24.4 Reconstructive surgery of NMSC Tilemachos Anthopoulos (Athens, Greece)

13:30-13:45 SY24.5 Combined curettage excision and cryosurgery for treatment of epithelial cancers of the skin Panagiotis Polyzois (Athens, Greece)

SATURDAY, MAY 6, 2017 BANQUET HALL 13:45 CONGRESS CLOSURE

36 13th Congress of the EADO • Athens, Greece Final Programme 37 WEDNESDAY THURSDAY FRIDAY SATURDAY EADO European Association of MAY 3 MAY 4 MAY 5 MAY 6 Dermato Oncology

FREE COMMUNICATIONS CATALOGUE E-POSTERS CATALOGUE SATURDAY, MAY 6, 2017

36 13th Congress of the EADO • Athens, Greece Final Programme 37 FREE COMMUNICATIONS

FREE COMMUNICATIONS 1 Non-melanoma skin cancer: Merkel cell carcinoma, CTCL, rare skin tumours

FC1.1 The transgenic HPV8 Mouse skin is FC1.5 Cutaneous mosaic syndromes associated with Lrig1 keratinocyte associated with early postzygotic stem cell expansion activating BRAF mutations Girish Patel, Simone Lanfredini, Paul Kuentz, Jean-Baptiste Riviere, Carlotta Olivera, Cinzia Borgogna, Arthur Sorlin, Virginie Carmignac, Fredrica Calati, Kathryn Powell, Thibaud Jouan, Jeanne Amiel, Olivia Kelli-Jo Davies, Marco De Andrea, Boccara, Sylvie Fraitag, Annabel Sarah Harries, Hiu Kwan Carolyn Maruani, Laurence Faivre, Pierre Tang, Herbert Pfister, Marisa Gariglio Vabres (France & Canada) (United Kingdom & Germany) FC1.6 The value of genetic testing FC1.2 The polycomb proteins RING1B and in patients with basal cell EZH2 repress the tumoral nevus syndrome: A multicenter proinflammatory function in retrospective cohort study metastatic cutaneous squamous cell Betül Cosgun, Marieke Reinders, carcinoma Klara Mosterd (The Netherlands) Agusti Toll, Eugenia Hernandez- Ruiz, Irene Garcia-Diez, Evelyn FC1.7 The heterogenous immune Andrades, Carla Ferrandiz-Pulido, landscape of mycosis fungoides Emili Masferrer, Mireia Yebenes, Ane Duncan Murray, Andrew Beggs, Jaka, Javier Gimeno, Ramon Gimeno, Nathaniel Davies, Suzy Eldershaw, Vicenc Garcia-Patos, Ramon M. Jack McMurray, Hayden Pearce, Pujol, Inmaculada Hernandez-Munoz Joanne Stockton, Jinah Yoo, Julia (Spain) Scarisbrick, Paul Moss (United Kingdom) FC1.3 Merkel cell carcinomas are RESTless FC1.8 Interferon alpha remains an Emil Chteinberg, Christopher effective treatment for early stage Sauer, Lisa Schiffelers, Jonathan refractory mycosis fungoides (MF), Eben, Dorit Rennspiess, Veronique advanced MF and Sezary Syndrome Winnepenninckx, Ernst-Jan Speel, Marianne de Brito (United Kingdom) Anna Kordelia Kurz, Martin Zenke, Axel zur Hausen (The Netherlands FC1.9 Prospective pilot study & Germany) evaluating the effectiveness of electrochemotherapy using reduced FC1.4 Treatment and survival of 351 dosages of intravenous bleomycin patients with Merkel cell carcinoma Roberta Rotunno, Francesca in 2 expert-centers Deterlizzi, Simone Ribero, Luca Linde van Veenendaal, Alexander van Campana, Pietro Quaglino, Christian Akkooi, Cornelis (Cees) Verhoef, Dirk Kunte, See Hwang Liew, Joy Odili, Grünhagen, Martin Klop, Gerlof Valk, Julie Gehl, Pietro Curatolo (Italy,

Margot Tesselaar (The Netherlands) Germany, United Kingdom, Denmark)

38 13th Congress of the EADO • Athens, Greece Final Programme 39 EADO FC European Association of Dermato Oncology

FREE COMMUNICATIONS 2 Topics in Dermato-oncology Late breaking abstracts

FC2.1 Tumor-stroma based prognosis FC2.5 Routine management of adverse in primary cutaneous melanoma: effects during treatment with the Validation and exploratory analysis hedgehog inhibitor Vismodegib: of an eight-gene risk score A single center experience Thomas Dirschka, Georg Brunner, Nadja Pichler, Teresa Deinlein, Ingrid Uwe Reinhold (Germany) Wolf, Iris Zalaudek (Austria)

FC2.2 Clinical characteristics associated FC2.6 Relationship between talimogene with Spitz nevi, atypical Spitz laherparepvec and intratumoural nevi and melanomas in patients CD8+ density in patients with younger than 20 years: A 15-year unresectable stage IIIB-IVM1c retrospective study from «Andreas melanoma: Interim efficacy, safety Sygros» Hospital (2004 to 2016) and biomarker results of a Phase 2 Efthymia Soura, Michaela Plaka, study Christina Stefanaki, Vassiliki Chasapi, Josep Malvehy, Igor Samoylenko, Dorothea Polydorou, Erietta Dirk Schadendorf, Ralf Gutzmer, Christofidou, Othon Papadopoulos, Jean-Jacques Grob, Joseph Sacco, Christina Antoniou, Alexander J. Kevin S. Gorski, Cheryl A. Pickett, Stratigos (Greece) Kate Liu, Helen Gogas (Spain, Russian Federation, Germany, FC2.3 The insidence of false negative France, United Kingdom, USA, sentinel lymph node biopsy in Greece) melanoma and its impact on the treatment of the disease FC2.7 Evaluation of melanocitic tumours Parthena Deskoulidi, Pantelis in chronic graft versus host disease Diamantopoulos, Michael Kidonakis, patients. A clinical challenge for Konstantinos Pistolas, Georgios dermatologist Koumakis, Dimitrios Trifonopoulos, Alicia Barreiro-Capurro, Jose Manuel Niki Arnogiannaki, Evelina Skafida, Mascaró-Galy, Beatriz Alejo Galindo, Dora Petrakopoulou, Georgios Cristina Carrera, Susana Puig, Josep Zarkadas (Greece) Malvehy (Spain)

FC2.4 Sonidegib’s duration of response: FC2.8 Sarcoid-like reactions under Results from the pivotal phase modern melanoma treatment 2 BOLT study over 30 months in Florentia Dimitriou, Anna Frauchiger, patients with locally advanced basal Simone Maria Goldinger, Ralph cell carcinoma Braun, Joanna Mangana, Reinhard Michael Migden (USA) Dummer (Switzerland)

38 13th Congress of the EADO • Athens, Greece Final Programme 39 FREE COMMUNICATIONS

FREE COMMUNICATIONS 3 Non-melanoma skin cancer: Basal cell and squamous cell carcinoma

FC3.1 Health-Related Quality of Life FC3.4 Comparison of long-term aesthetic (HRQoL) analysis by Skindex-16 in outcomes for different treatments MIKIE, long-term follow-up from of superficial basal cell carcinoma the randomized, phase 2 study Maud Jansen, Fabienne Koekelkoren, to assess the efficacy and safety Patty Nelemans, Aimee Arits, of two intermittent vismodegib Marieke Rozzeboom, Nicole regimens in patients with multiple Kelleners-Smeets, Klara Mosterd Basal Cell Carcinomas (BCCs) (The Netherlands) Dirk Schadendorf, Axel Hauschild, Scott Fosko, David Zloty, Bruno FC3.5 Insights from RegiSONIC on the Labeille, Jean-Jacques Grob, Susana diagnosis and treatment of locally Puig, Martina Makrutzki, Frank Gilberg, advanced basal cell carcinoma by Brigitte Dréno, Gary Rogers, Rainer type of practice Kunstfeld (Germany, USA, Canada, Aleksandar Sekulic, Thomas Olencki, France, Spain, Switzerland, Austria) Gary Rogers, Julie Guillen, Simon Yoo, Ragini Kudchadkar, Yong Mun, FC3.2 Long-ter m follow-up from MIKIE: Qian (Cindy) Zhu, Laura Chu, Keith A randomized, double-blind, phase Dawson, Mario Lacouture (USA) 2 study to assess the efficacy and safety of two intermittent vismodegib FC3.6 Retr ospective chart review to regimens in patients with multiple characterize real-world patients Basal Cell Carcinomas (BCCs) with difficult-to-treat (dt) Basal Cell Rainer Kunstfeld, Gary Rogers, Carcinoma (BCC) who are potential Brigitte Dréno, Axel Hauschild, Scott candidates for Hedgehog Pathway Fosko, David Zloty, Bruno Labeille, Inhibitors (HPIs) Jean-Jacques Grob, Susana Puig, Jean-Jacques Grob, John Lear, Martina Makrutzki, Frank Gilberg, Alexander Guminski, Valerie C. Dirk Schadendorf (Austria, USA, Amann, Reinhard Dummer, Arundhati France, Germany, Canada, Spain, Soman (France, United Kingdom, Switzerland) Australia, Switzerland, USA)

FC3.3 Corr elation between clinical and FC3.7 Recent developments in the histological patterns in 2710 management of patients with basal cell carcinomas: A French squamous cell skin carcinoma risk: multicentric prospective study The Greek 10-year experience in Lea Dousset, Jean-Michel Amici, squamous cell carcinoma of two Bernard Cribier, Maxime Battistella, centers Beatrice Vergier, Jean-Yves Bailly, Emmanouil Dimonitsas, Gregory Olivier Cogrel, Laurence Gusdorf, Champsas, Ortansia Doryforou, Christine Alfaro, Khaled Ezzedine, Dimitrios Papakostas, Andriani-Eleni Marie Beylot-Barry (France) Trigka, Eirini Thymara, Penelope

40 13th Congress of the EADO • Athens, Greece Final Programme 41 EADO FC European Association of Dermato Oncology

Korkolopoulou, Despoina Kakagia, FC3.9 Safety of ingenol mebutate Nikolaos Papadopoulos, Othon compared to diclofenac for patients Papadopoulos, Alexander with actinic keratosis on the face J. Stratigos (Greece) or scalp Eggert Stockfleth, Catherine FC3.8 Ef ficacy of ingenol mebutate Harwood, Carlos Serra-Guillen, compared to diclofenac for patients Thomas Larsson, Marie Louise with actinic keratosis on the face Østerdal, Torsten Skov (Germany, or scalp United Kingdom, Spain, Denmark) Eggert Stockfleth, Catherine Harwood, Carlos Serra-Guillen, Thomas Larsson, Marie Louise Østerdal, Torsten Skov (Germany, United Kingdom, Spain, Denmark)

FREE COMMUNICATIONS 4 Melanoma

FC4.1 Der moscopy of melanoma in situ FC4.4 Baseline neutrophil-lymphocyte Chrysoyla Papageorgiou, Aimilios ratio is associated with metastases Lallas, Zoe Apalla, Efstratios Vakirlis, of cutaneous melanoma to the Gurpreet Variaah, Elena Sotiriou, sentinel lymph node Elizabeth Lazaridou, Demetrios Alyss V. Robinson, Claire Keeble, Ioannides (Greece, Bulgaria) Maria Marples, Donald Dewar, Howard Peach, Ryckie G. Wade FC4.2 In situ evaluation of markers of (United Kingdom) activation and inhibition of Tumor Infiltrating Lymphocytes (TILs) after FC4.5 Novel germline variants in microdissection: Remarks to the cutaneous and uveal melanoma current morphologic classification families of the «TILs patterns» Nicholas Hayward, Antonia Pritchard, Francesca Maria Bosisio, Jasper Peter Johansson, Lauren Aoude, Wouters, Marguerite Stas, Göran Jonsson, Veronica Höiöm, Maddalena Bolognesi, Carla Scalia, Karin Wadt (Australia, Sweden, Joost van den Oord (Belgium, Italy) Denmark)

FC4.3 Pr eliminary in vitro-data indicating FC4.6 TRILOGY/IMspir e150: A phase a potential protumorigenic 3, double-blinded, randomized function for 4-1BBL+ melanoma study of atezolizumab (A) plus subpopulations cobimetinib (C) combined with Panagiotis Kampilafkos, Karin vemurafenib (V) vs placebo plus Scharffetter-Kochanek, Brian J.Wilson, C combined with V in previously Jorg Schaller, Natasha Y. Frank, untreated BRAFV600 mutation- Markus H. Frank (Germany, USA) positive patients with locally

40 13th Congress of the EADO • Athens, Greece Final Programme 41 FREE COMMUNICATIONS

advanced or metastatic melanoma FC4.8 Association of depth of response (NCT02908672/EudraCT 2016- with survival outcomes in prognostic 002482-54) groups of patients treated with Paolo Ascierto, Karl Lewis, Grant cobimetinib (C) ± vemurafenib (V): McArthur, Isabelle Rooney, Virginia A pooled analysis of the BRIM-2, -3, McNally (Italy, USA, Australia, United -7, and coBRIM studies Kingdom) Karl D. Lewis, James Larkin, Antoni Ribas, Keith T. Flaherty, Grant A. FC4.7 Retr ospective medical record McArthur, Paolo A. Ascierto, Brigitte review of melanoma patients Dréno, Edward McKenna, Qian Zhu, with BMs treated with SRS or Yong Mun, Axel Hauschild (USA, WBR in combination with immune United Kingdom, Australia, Italy, checkpoint inhibitors (ICI) or BRAF France, Germany) +/- MEK inhibitors (BRAFi +/- MEKi) in the Departments of Radiation FC4.9 Evaluation of circulating microRNAs Oncology and Dermatooncology as diagnostic circulating biomarkers of the University Hospital Dresden in cutaneous melanoma from March 2014 to March 2016 Beatrice Polini, Stefano Fogli, Sara R. Rauschenberg, M. Chapsa, Carpi, Barbara Pardini, Alessio M. Garzarolli, S. Beissert, E. Troost, Naccarati, Nevio Dubbini, M. Cristina F. Meier (Germany) Breschi, Antonella Romanini, Paola Nieri (Italy)

42 13th Congress of the EADO • Athens, Greece Final Programme 43 EADO E-P E-POSTERS CATALOGUE European Association of Dermato Oncology

CUTANEOUS LYMPHOMAS

Syndrome (SS) that have achieved P001 Risk factors for skin infections in mycosis fungoides disease control with systemic Eve Lebas, Jorge E. Arrese, Arjen therapy – The RESMAIN Study F. Nikkels (Belgium) Rudolf Stadler, Julia Scarisbrick, Robert Knobler, Pietro Quaglino, P002 First line phototherapy in early Matthias Borgmann, Martin Orlovius, stage MF patients: The results of a Babett Krauss, Susanne Danhauser- large cohort retrospective study Riedl (Germany, United Kingdom, Vasiliki Nikolaou, Athanasios Sachlas, Austria, Italy, Germany) Evangelia Papadavid, Afroditi Economidi, Konstantina Karambidou, P006 Cutaneous CD30 positive Leonidas Marinos, Alexander lymphoproliferative disorders: J. Stratigos, Christina Antoniou Diagnostic challenges (Greece) Alexandra-Sinziana Dumitru, Irina Margaritescu, Teodora Predescu, P003 Results of radiotherapy for Calin Giurcaneanu, Ana-Maria Forsea localized primary cutaneous B cell (Romania) lymphomas Hanene Ben Salah, Manel Bahri, Lilia P007 The link between chronic Ghorbel, Moez Elloumi, Jamel Daoud inflammatory dermatoses and (Tunisia) cutaneous T-cell lymphoma? Case reports and discussion P004 Optical coherence tomography - Mara Madalina Mihai, Ana-Maria Potential roles in the non-invasive Forsea, Irina Margaritescu, Olguta diagnosis of mycosis fungoides Anca Orzan, Liliana Gabriela Popa, Andria Pehoiu, Ioanna Popescu, Diana Sabina Radaschin, Monica Irina Salem, I. Margaritescu, Teodora Dima, Calin Giurcaneanu (Romania) Predescu, Alin Nicolescu, Calin

Giurcaneanu, Ana Maria Forsea P008 Coexistence of lymphomatoid (Romania) papulosis, pityriasis lichenoides acuta and mycosis fungoides – P005 A multicentre, double blind, randomised, placebo controlled, A case report Phase II trial to evaluate Dimitra Voudouri, Vasiliki Nikolaou, Resminostat for maintenance Leonidas Marinos, Evangelia treatment of patients with Papadavid, Afroditi Economidi, advanced stage (Stage IIB - IVB) Alexander J. Stratigos, Christina mycosis fungoides (MF) or Sezary Antoniou (Greece)

42 13th Congress of the EADO • Athens, Greece Final Programme 43 E-POSTERS CATALOGUE

GENERAL ASPECTS OF SKIN CANCER

P009 Subcutaneous nodules as first P014 The synthetic retinoid-polyamine manifestation of a metastatic conjugate RASP induces S/G2 cell bronchial carcinoma cycle arrest and DNA damage Ioannis Karagiannidis, Martina response on HaCat cells Brunner, Lars Seifert, Christos Katerina Grafanaki, Christos Kontos, Zouboulis (Germany) Korfiati Aigli, Athanasios Shaukat, Dionissios Papaioannou, Andreas P010 Atypical presentation of melanoma Scorilas, Constantinos Stathopoulos, and non-melanoma skin cancer as Denis Drainas (Greece) chronic non healing ulcers Themis Sgontzou, Efthymia P015 Anti-PD1/PDL1 induced psoriasis Agiasofitou, Fotini Liordou, Iakovoula Dimitra Voudouri, Vasiliki Nikolaou, Chatzimichael, Eftychia Zouridaki Konstantinos Laschos, Andrianni (Greece) Charpidou, Nikolaos Soupos, Ioanna Triantafyllopoulou, Ioanna P011 Paget’ s disease of the nipple: Not Panoutsopoulou, Sotirios Tsimpoukis, just an eczema Gerasimos Aravantinos, Konstantinos Ortansia Doryforou, Emmanouil Dimonitsas, Athanasios Roulias, Syrigos, Alexander J. Stratigos Emmanouil Seferos, Ioannis Kapiris (Greece) (Greece) P016 Pityriasis Lichenoides Et P012 Pyoder ma gangrenosum on the Varioliformis Acuta (PLEVA) during head – Diagnosis “per exclusionem” therapy with immunomodulatory Katarina Adamicova, Zelmira agent targeting PD1 – A case Fetisovova, Dagmar Statelova, Juraj report Pec, Martina Bobrovska (Slovak Dimitra Voudouri, Vasiliki Nikolaou, Republic) Emmanouil Xydakis, Leonidas Marinos, Ioanna Triantafyllopoulou, P013 Oncoder matology specialized clinic Ioanna Panoutsopoulou, Gerasimos at «A. Sygros» University Hospital: Aravantinos, Alexander J. Stratigos Epidemiologic data from the first 2 (Greece) operational years Ioanna Triantafyllopoulou, Ioanna G. Panoutsopoulou, Vasiliki Nikolaou, Panagiotis Diamantopoulos, Helen Gogas, Christina Antoniou, Alexander J. Stratigos (Greece)

44 13th Congress of the EADO • Athens, Greece Final Programme 45 EADO E-P European Association of Dermato Oncology

MELANOMA

P017 Cytokine pattern for improving Gitta Panczel, Timea Balatoni, Peter immuno-score in melanoma patients Szavcsur, Gabriella Liszkay (Hungary) Monica Neagu, Carolina Constantin, Constantin Caruntu, Mihaela Surcel, P023 A wareness and attitudes of Cypriots Daniel Boda, Sabina Zurac (Romania) on sun protection and melanoma Demetra Kyprianou, Iris Charalambidou, P018 MVsnaclec, a novel C-type lectin Paraskevi Farazi (Cyprus, USA) protein from Macrovipera lebetina venom, inhibits proliferation, P024 Baseline neutrophil-lymphocyte, induces apoptosis and suppresses platelet-lymphocyte and migration in SK-MEL-28 human lymphocyte-monocyte ratios and melanoma cells survival in cutaneous malignant Manel Ben Hammouda, Ichrak Riahi melanoma Chebbi, Soumaya Souid, Zohra Aloui, Alyss Robinson, Claire Keeble, Maria Maia Fernanda Montenegro, Habib Marples, Donald Dewar, Howard Karoui, Ammar Gasmi, Jose Neptuno Peach, Ryckie Wade (United Kingdom) Rodriguez Lopez, Khadija Essafi Benkhadir (Tunisia, Spain) P025 Melanin-biosynthesis substrate, cysteaminylphenol, NPrCAP for P019 Anymal-type melanoma (pigment- exploiting melanoma-targeting synthesizing melanoma): A report drug and its conjugation with of 3 cases magnetite nanoparticles for Jelena Stojkovic-Filipovic, Martina developing melanoma chemo- Bosic, Dimitrije Brasanac (Serbia) thermo-immunotherapy Kowichi Jimbow (Japan) P020 Application of dermoscopy for optimization of early diagnosis of P026 Age and anatomical location melanoma in Belarus related dermoscopic patterns Andrei Prakoshyn, Aliaxandr of 210 acral melanocytic nevi in Zhukavetz, Nikalai Lud (Belarus) Turkish population Nazan Emiroglu, Fatma Pelin Cengiz, P021 Melanoma in special situations (unusual progression of metastatic Nahide Onsun (Turkey) melanoma) Eleni Panagiota Chamalidou, Fotini P027 Sudden eruption of multiple Papaeuthymiou, Dimitrios Kasarakis seborrheic keratoses and actinic (Greece) keratoses in a patient treated with dabrafenib P022 Results achieved by intra-arterial Maria Isabela Sarbu, Mircea Tampa, chemotherapy in 50 ocular Madalina-Irina Mitran, Cristina-Iulia melanoma patients with metastases Mitran, Vasile Benea, Simona-Roxana localised in the liver. Single institute Georgescu (Romania) retrospective study

44 13th Congress of the EADO • Athens, Greece Final Programme 45 E-POSTERS CATALOGUE

Pantelis Diamantopoulos, Nikolaos P028 Synchr onous malignant tumours Maltzaris, Dimitrios Agorogiannis, of different genesis in ipsilateral Konstantinos Benetatos, Maria axillary lymph nodes Kotrotsiou, Christos Klonaris, Emmanouil Dimonitsas, Gregory Athanasios Korogiannos, Georgios Charitos, Ortansia Doryforou, Koumakis, Panagiotis Gouveris, Konstantina Fragia-Tsivou, Spiros Stavrianos, Georgios Zarkadas Konstantinos Avraam, Florentia (Greece) Fostira, Nikolaos Kentepozidis, Irene Stefanaki, Alexander J. Stratigos, P034 Acral lentiginous melanoma - A skin Dimitrios Vougiouklakis, Ioannis cancer with unfavourable prognostic Kapiris (Greece) features. A study of the German Central Malignant Melanoma P029 Mobile digital dermatoscopy in vivo Registry (CMMR) in 2050 patients for the diagnosis of melanoma Yukiko Teramoto, Ulrike Keim, Lina Ivert, Martin Gumulka, Martin Matthias Goebeler, Georg Schuler, Stichenwirth, Magnus Alderling, Eckhard Fiedler, Thomas Tuting, Johan Heilborn, Jan Lapins (Sweden) Claas Ulrich, Uwe Wollina, Jessica Hassel, Ralf Gutzmer, Sergej Goerdt, P030 Mass spectrometry imaging: From Christos Zubulis, Thomas Eigentler, skin cancer to melanoma Ulrike Leiter, Claus Garbe Rima Ait-Belkacem, Xavier Thuru Florian Farcette, Jonathan Stauber P035 The peripheral blood TCR (France) repertoire might facilitate patient stratification for immune P031 Do stage III melanoma patients checkpoint blockade inhibition in with melanoma of unknown primary metastatic melanoma have better survival than patients Sabrina Schindler, Anais Courtier, with melanoma of known primary? Nicoletta Jaberg-Bentele, Simone Jes C. Rodgaard, Ulrik Kjerkegaard, Goldinger, Manuarii Manuel, Solene Jens A. Sorensen, Lars B. Stolle Perez, Jean-Francois Mouret, Thi (Denmark) Dan Linh Nguyen-Kim, Marieke Raaijmakers, Pia Kvistborg, Nicolas P032 Do stage IV melanoma patients Pasqua, John Haanen, Reinhard with melanoma of unknown primary Dummer, Mitchell Levesque have better survival than patients (Switzerland, France, The Netherlands) with melanoma of known primary? Jes C. Rodgaard, Ulrik Kjerkegaard, P036 Neur on-specific enolase (NSE) as Jens A. Sorensen, Lars B. Stolle serological marker in patients with (Denmark) metastatic malignant melanoma Sayuri Sato, Junji Kato, Mao Yamada, P033 Head and neck melanoma Masahide Sawada, Hitomi Takahashi, Parthena Deskoulidi, Thaleia Shiori Kamiya, Kouhei Horimoto, Nikolaidou, Michael Kydonakis, Hisashi Uhara (Japan)

46 13th Congress of the EADO • Athens, Greece Final Programme 47 EADO E-P European Association of Dermato Oncology

Thanos Papas, Bonnie Swan, Victoria P037 Efficacy of vemurafenib treatment in 43 metastatic melanoma patient Akhras, Joy Odili (United Kingdom) with BRAF mutation. Single- institute retrospective analysis, P042 Peripheral blood double positive T early real-life survival data with lymphocytes in melanoma patients 15.9 months follow up time treated with adjuvant interferon- Kata Czirbesz, Eszter Gorka, Gitta alpha Panczel, Krisztina Melegh, Peter Mariia Kukushkina, Svitlana Kovacs, Andras Gezsi, Gabriella Kukushkina, Feodosiy Fil`chakov, Liszkay (Hungary) Sergii Korovin, Ganna Lon, Katerina Shumilina (Ukraine) P038 Melanoma-associated hypopigmentation as sign of P043 Clinical and dermoscopic EMT-propelled metastatic spread: monitoring of pigmented and Towards identification of the amelanotic Spitz naevi in children molecular particularities Elodie Bouassi, Bertille Bonniaud, Katharina Furst, Marc Steder, Stella Marie-Helene Aubriot-Lorton, Logotheti, Stefan Marquardt, David Geraldine Jeudy, Blandine Bel, Engelmann, Brigitte M. Putzer Pierre Vabres (France) (Germany) P044 Dermoscopy of small and medium P039 Thin melanoma in Swiss patients: congenital melanocytic nevi in A clinicopathological comparison infants and children Corina Kaufmann, Joanna Mangana, Elodie Bouassi, Bertille Bonniaud, Phil Cheng, Egle Ramelyte, Simone Maxime Luu, Sophie Dalac-Rat, M. Goldinger, Mitch P. Levesque, Geraldine Jeudy, Pierre Vabres Reinhard Dummer (Switzerland, (France) Lithuania)

P045 Sentinel lymph nodes biopsy for P040 Galvanotherapy effectively thin skin melanoma (single-institute necrotizes cutaneous melanoma metastases and has the potential as experience) an tumor antigen releasing therapy Sergii Korovin, Mariia Kukushkina, Ioanna Tampouri, Maximilian Andrii Palivets, Vasyl Ostafiichuk, Gassenmaier, Heike Niessner, Tobias Svitlana Kukushkina, Sergii Boichuk Sinnberg, Ioannis Thomas, Claus (Ukraine) Garbe (Germany) P046 Dysplastic nevi and their relationship P041 Unusual case of spreading with skin melanoma in population of melanosis in a previously excised northern part of Serbia melanoma of the upper limb and Zlata Janjic, Jelena Nikolic, Marija treatment with combined topical Marinkovic, Borislava Nikolin, immunotherapy Dragana Lekovic (Serbia)

46 13th Congress of the EADO • Athens, Greece Final Programme 47 E-POSTERS CATALOGUE

Carla Barcelo, Oscar Maiques, Anais P047 Ki 67 proliferative index in the invasive portion of melanoma as a Panosa, Jordi Pijuan, Jose Luis Orgaz, predictive biomarker for sentinel Ramon Vilella, Angels Fabra, Susana node and non-sentinel node positivity Puig, Victoria Sanz-Moreno, Xavier Eduardo Bertolli, Mariana Petaccia Matias-Guiu, Judit Herreros, Carles de Macedo, Clovis Antonio Lopes Canti, Anna Macia, Rosa Maria Marti Pinto, Joao Pedreira Duprat Neto (Spain, United Kingdom) (Brazil) P052 Profile response to Vemurafenib P048 Differential immunoexpression of melanoma patients with a BRAF of senescence markers, tumor D594N mutation suppressor genes, BRAF-V600E Melanie Saint-Jean, Audrey Vallee, and T-type calcium channels in Gaelle Quereux, Lucie Peuvrel, acquired nevi according to their Sandrine Charpentier, Amir histopathological and dermoscopic Khammari, Marc G. Denis, Brigitte classification Dréno (France) Oscar Maiques, Sara Moreno, Marta Romero, Maria Santacana, Ignacio P053 Vitiligo-like lesions occurring in Gomez, Anna Velasco, Anna Macia, patients receiving anti-programmed Carla Barcelo, Ramon Boix, Joan cell death-1 therapies are clinically Valls, Sonia Gatius, Carles Canti, and biologically distinct from vitiligo Xavier Matias-Guiu, Xavier Soria, Lea Dousset, Maiana Larsabal, Rosa Maria Marti (Spain) Aurelie Marti, Clement Jacquemin, Jerome Rambert, Denis Thiolat, Alain P049 Pr ediction of sentinel lymph node Taieb, Sorilla Prey, Caroline Dutriaux, status by patient`s and primary Katia Boniface, Julien Seneschal tumor characteristics in cutaneous (France) melanoma - A single center study Ljiljana Jaukovic, Milica Rajovic, P054 Cancer gene therapy: The Lidija Kandolf Sekulovic, Goran Sijan, Marija Radulovic, Nenad Stepic estimation of reporter genes (Serbia) delivery to B16-F10 melanoma cells Milena Czajka, Agnieszka Zajkowska, P050 Long-ter m outcome estimation Natalia Stachowiak, Maciej Malecki combining real world with clinical (Poland) trial data in metastatic melanoma following a Bayesian approach P055 New insights on the management Yovanna Castro (Switzerland) of cutaneous adverse events of BRAF and MEK inhibitors alone and P051 T-type calcium channel blockers in combination used in metastatic reduce migration/invasion in melanoma BRAFV600E melanoma cells by Nikolaos Makris (Greece) inhibiting autophagy

48 13th Congress of the EADO • Athens, Greece Final Programme 49 EADO E-P European Association of Dermato Oncology

P056 Vemurafenib in metastatic P063 Survival of acral lentiginous melanoma treatment - Case report melanoma in the National Cancer Jelena Djedovic, Zoran Andric (Serbia) Institute of Colombia Carlos Duarte, Juanpablo Florez, P057 TOXICAN: A tool which aims to Hector Lopez, Ximena Meneses, improve grading of skin adverse Esther De Vries (Colombia) events during cancer treatments Lucie Peuvrel, Julie Cassecuel, Claire P064 A case of subungual longitudinal Bernier, Melanie Saint-Jean, Gaëlle melanonychia in a preschool child Quereux, Marie Le Moigne, Amir Ana Benedicic (Slovenia) Khammari, Brigitte Dréno (France) P065 DRESS syndrome induced with the P058 Current mutation testing combination of vemurafenib and approaches in metastatic melanoma cobimetinib in melanoma: A series and unmet need in the NRAS+ of 7 cases patient population in the US Barbara Bregeon, Lucie Peuvrel, Claire Maxim Sheinin, Tanuf Tembulkar, Bernier, Marie Lemoigne, Nicolas Zahra Alkhateeb, Nandini Hadker, Josselin, Melanie Saint-Jean, Helene Krista Perry, Herman Sanchez, Ira Aubert, Justine Daguze, Brigitte Steinberg (USA) Dréno, Gaelle Quereux (France)

P059 Survival of melanoma patients after P066 Surgical treatment of lymphedema false negative sentinel lymph node with microvascular lymph node biopsy Barbara Peric, Sara Milicevic, Janez transplantation: Preliminary results Zgajnar, Marko Hocevar (Slovenia) Nikolaos A. Papadopulos, Emmanouil Dimonitsas, Ioannis Flessas, Paraskevi P060 Neoadjuvant photodynamical Liakou, Anastasia Pazaiti, Othon therapy in the surgical treatment Papadopoulos, Daniel Mueller, of patients with melanoma skin George Zografos (Greece, Germany) Irina Baldueva, Mark Gelfond, Georgy Gafton, Valentin Anisimov, P067 Bullous eruptions with nivolumab: Tatiana Nekhaeva, Mikhail 3 cases Myasnyankin (Russia) Lucie Peuvrel, Sarah Le Naour, Melanie Saint Jean, Claire Bernier, P061 Experience of surgical treatment of Anne Chantal Knol, Brigitte Dréno, subungual melanoma Gaelle Quereux (France) Mikhail Myasnyankin, Georgy Gafton, Valentin Anisimov, Dmitriy Matsko, P068 The need of detection of B-RAF Alexander Ivantsov (Russia) mutation in metastatic melanoma. Presentation of our experience and P062 A new look at surgical treatment of review of the literature patients with subungual melanoma Pantelis Diamantopoulos, Parthena Mikhail Myasnyankin (Russia) Deskoulidi, Konstantinos Pistolas,

48 13th Congress of the EADO • Athens, Greece Final Programme 49 E-POSTERS CATALOGUE

Michael Kydonakis, Athanasios P074 In-transit cutaneous metastases Korogiannos, Panagiotis Gkouveris, originating from a lentigo maligna Theodora Petrakopoulou, Georgios Dimitrios Sgouros, Alexander Zarkadas (Greece) Katoulis, Konstantinos Neamonitos, Ioannis Panayiotides, Dimitrios P069 Early onset melanoma: Experience Rigopoulos (Greece) from13 Greek patients with melanoma presenting before the P075 Special morphologic features of age of 20 polypoid melanoma mimicking Christina Stefanaki, Efthymia dermal nevus Soura, Vassiliki Chasapi, Michaela Dimitrios Sgouros, Maria Kefala, Plaka, Dorothea Polydorou, Othon Nikolaos Orfanos, Alexander Katoulis, Papadopoulos, Erietta Christofidou, Dimitrios Rigopoulos (Greece) Christina Antoniou, Alexander J. Stratigos (Greece) P076 The S100B protein as a melanoma biomarker predict independently P070 Dermoscopy vs unnecessary disease outcome in advanced stage surgical excisions Athanasios Karonidis, Marina Maria Kassini, Iakovos Antoniou, Mira Mantzourani, Helen Gogas, Kadurina, Nikolay Tsankov (Bulgaria, Dimosthenis Tsoutsos (Greece) Cyprus, Italy) P077 Oncogenic mutations in vulvar and vaginal melanomas P071 Multiple primary melanoma Maria Kassini, Iakovos Antoniou, Lucie Peuvrel, Sophie Wylomanski, Marc Denis, Sandrine Theoleyre, Zdravka Demerdzieva (Bulgaria, Rejane Bouquin, Anne-Chantal Knol, Cyprus) Brigitte Dréno, Gaelle Quereux (France) P072 Clinical behavior and prognosis in Spitzoid melanoma patients who P078 Efficient treatment of a metastatic underwent sentinel node biopsy melanoma patient with a Eduardo Bertolli, Diego Greatti Vaz combination of BRAF and MEK Silva, Bruno Luiz Galvao, Valter Junio inhibitors based on circulating Fiuza Machado, Luciana Facure tumor DNA analysis Moredo, Clovis Antonio Lopes Pinto, Lucie Peuvrel, Marc Denis, Guillaume Mariana Petaccia Macedo, Joao Herbreteau, Anne-Chantal Knol, Pedreira Duprat Neto (Brazil) Audrey Vallee, Amir Khammari, Sandrine Theoleyre, Melanie Saint- P073 Melanoma on a giant congenital Jean, Brigitte Dréno, Gaelle Quereux melanocytic nevus with proliferative (France) nodules: Is it truly melanoma? Larisa Georgiana Muresan, Irina P079 Our clinical experience with targeted Condrat, Ancuta Niculi, Rodica Maria tumor treatment in patients with Cosgarea (Romania) BRAF-mutant metastatic melanoma

50 13th Congress of the EADO • Athens, Greece Final Programme 51 EADO E-P European Association of Dermato Oncology

Henriette Ocsai, Eszter Baltas, Anita P086 Simultaneous occurrence of two Varga, Lajos Kemeny, Judit Oláh primary, symmetric melanoma in a (Hungary) 75 year old man. Case report

Anna Pogorzelska-Antkowiak, P080 BRG1 and INI1 expression in Ryszard Antkowiak, Lukasz Antkowiak metastatic melanoma (Poland) Thomas Flotte, Debra Bell (USA)

P087 The role of phosphohistone H3 P081 The dual role of Metformin as an adjuvant in photodynamic therapy immunostaining (pHH3) as a mitotic against melanom rate marker in cutaneous melanomas Diana Tudor, Iuliana Nenu, Adriana with Breslow Index greater than Filip, Diana Olteanu, Ioana Baldea 1.0 mm (Romania) Natalia Rompoti, Tobias Schimming, Elisabeth Livingstone, Dirk P082 Amelanotic naevoid melanoma Schadendorf, Uwe Hillen (Greece, arising from a medium sized Germany) congenital naevus in a young woman Maria Politou, Andriani Tsiakou, Maria P088 Clinicopathologic characteristics Pompou, Nikos Fekkas (Greece) and prognostic factors for thin cutaneous melanoma: Retrospective P083 Toll like receptors gene variants are single-institution analysis potential prognostic and outcome Tatjana Radevic, Milica Rajovic, biomarkers in melanoma patients Zorana Kremic, Ivana Ilijin, Ljubica Gordana Supic, Nikola Ostojic, Lidija Jevremovic, Zeljko Mijuskovic, Lidija Kandolf-Sekulovic, Tatjana Vukanovic, Kandolf-Sekulovic (Serbia) Milica Rajovic, Zeljko Mijuskovic, Zvonko Magic (Serbia) P089 The surgical treatment of particular located cutaneous melanoma (PLCM): P084 Outcome following discontinuation Our experience over a 32 year period of pembrolizumab in advanced Grigorios Champsas, Epameinondas melanoma patients in the absence Kostopoulos, Christos Agianidis, of progressive disease: A single Marios Frangoulis, Emmanouil centre experience Dimonitsas, Giorgos Vakis, Alexander Yanina Jansen, Odrade Gondry, J. Stratigos, Othon Papadopoulos Simon Planken, Teofila Seremet, Bart (Greece) Neyns (Belgium)

P085 The old reliables outperform P090 Melanoma in Groin new media in social marketing of Z. M. Nedic, M. Mitrovic (Serbia) Euromelanoma in Ireland Lisa Roche, Catherine C. Foley, Siobhan McCarthy, Michelle Murphy (Ireland)

50 13th Congress of the EADO • Athens, Greece Final Programme 51 E-POSTERS CATALOGUE

NON-MELANOMA SKIN CANCER

P091 Systemic review and meta-analysis P097 Correlation of clinical, dermoscopical of MC1R gene variants, skin color and histopathological features of all and basal cell carcinoma risk subtypes of basal cell carcinoma Clio Dessinioti, Klea Katsouyanni, Didem Dizman, Dilek Biyik Ozkaya, Alexander J. Stratigos (Greece) Anil Gulsel Bahali, Bugce Topukcu Dizman, Pelin Yildiz, Zeynep Tosuner, P092 Verrucous Bowen’s disease on groin Cuyan Demirkesen, Nahide Onsun, with dermoscopic and siascopic Ozlem Su (Turkey) images Fatma Pelin Cengiz, Nazan Emiroglu, P098 Advanced head and neck squamous Ozlem Su, Nahide Onsun (Turkey) and basal cell carcinomas Pantelis Diamantopoulos, Parthena P093 Efficacy of Isolated Limb Perfusion Deskoulidi, Nikolaos Maltzaris, (ILP) in patients with Merkel Cell Thaleia Nikolaidou, Maria Kotrotsiou, Carcinoma (MCC): A multicenter Konstantinos Benetatos, Nikolaos experience Koufopoulos, Spyridon Stavrianos Linde van Veenendaal, Max Madu, (Greece) Margot Tesselaar, Cornelis (Cees) Verhoef, Dirk Grünhagen, Alexander P099 Development of resistance to van Akkooi (The Netherlands) vismodegib after treatment interruption in advanced orbital P094 Actinic keratosis, carcinoma in basal-cell carcinoma situ andcutaneous squamous cell Timea Balatoni, Gabriella Liszkay carcinoma: Studying quality of life (Hungary) Olena. Oshyvalova (Ukraine) P100 Predicting response to vismodegib P095 Safety and efficacy of imiquimod before treatment initiation based 3.75% in a cohort of Greek patients on baseline characteristics in with actinic keratosis patients with metastatic basal cell Angeliki Befon, Vassiliki Tzanetakou, carcinoma in a pooled analysis Antonios Panagiotopoulos, Vasiliki Jean-Jacques Grob, Johan Hansson, Chasapi, Christina Antoniou, Nicole Basset-Seguin, Rainer Alexander J. Stratigos (Greece) Kunstfeld, Brigitte Dréno, Laurent Mortier, Paolo Ascierto, Lisa Licitra, Christian Hertig, Natalie Dimier, P096 Comparative characteristics of human papillomavirus of Beta Alberto Fittipaldo, Axel Hauschild subtype in patients with basal cell P101 Five year follow up for non- carcinoma (BCC) and seborrheic superficial basal cell carcinomas ≤20 keratosis (SK) both in tumours and mm in maximal diameter treated intact skin with Immunocryosurgery Tatiana Pisklakova, Elena Kostenko, Georgios Gaitanis, Ioannis Bassukas Larisa Telesheva (Russia) (Greece)

52 13th Congress of the EADO • Athens, Greece Final Programme 53 EADO E-P European Association of Dermato Oncology

P102 Immunocryosurgery for basal cell P108 Results of curative radiotherapy of carcinoma located on the ear: An cutaneous epidermoid carcinomas: effective, versatile, non-surgical About a series of 40 cases and modality for a difficult localization review of the literature Georgios Gaitanis, Panagiota Fatma Dhouib, Hanene Ben Salah, Tsintzou, Ioannis Bassukas (Greece) Manel Bahri, Abdelmonem Ghorbel, Jamel Daoud (Tunisia) P103 Multiple cutaneous squamous cell carcinomas as a consequence of P109 Case report: Pleomorphic prolonged immunosuppression dermal sarcoma and atypical during treatment of resistant fibroxanthoma. Different entities or bullous pemphigoid a spectrum of the same pathology? Elisabeth Lazaridou, Sofia Magdalini Farhana Kapasi, Marta Cabral, Phillip Manoli, Elena Sotiriou, Efstratios Ameerally (United Kingdom) Vakirlis, Aaggeliki Tsorova, Zoe Apalla, Aimilios Lallas, Demetrios P110 Results of curative postoperative Ioannides (Greece) radiotherapy in the treatment of cutaneous epidermoid carcinomas P104 A Marjolin’s ulcer on a burn site 73 Hanene Ben Salah, Fatma Dhouib, years later Manel Bahri, Abdelmonem Ghorbel, Emmanouil Dimonitsas, Gregory Jamel Daoud (Tunisia) Charitos, Konstantinos Avraam, Nikolaos Kentepozidis, Penelope P111 Non-melanoma skin cancer in the Korkolopoulou, Alexander J. head and neck: Case series of Stratigos (Greece) reconstructive challenges Urooj Iqbal, Farhana Kapasi, Phillip P105 Forequarter amputation (Berger’s Ameerally (United Kingdom) surgery) for locally advanced squamous cell carcinoma – Case P112 Post-operative aesthetic outcomes report and literature review in non-melanoma skin cancer of the Eduardo Bertolli, Marina Sonagli, head and neck: A comparison of Ana Carolina Anacleto Falcao, Joao patient and clinician perspectives Pedreira Duprat Neto (Brazil) Farhana Kapasi, Carmen Vallejo, Phillip Ameerally (United Kingdom) P106 Locally advanced skin tumours of head and neck-surgical viewpoint P113 Results of curative exclusive Predrag Kovacevic (Serbia) radiotherapy in the treatment of skin squamous cell carcinoma: P107 Vismodegib resistant basal cell About a series of 26 cases and carcinoma in Gorlin syndrome review of the literature Kelly Sinx, Renske Janssen, Michel Hanene Ben Salah, Fatma Dhouib, van Geel, Klara Mosterd Manel Bahri, Abdelmonem Ghorbel, (The Netherlands) Hamida Turki, Jamel Daoud (Tunisia)

52 13th Congress of the EADO • Athens, Greece Final Programme 53 E-POSTERS CATALOGUE

Theofani Koutsoukou, Antonios P114 Squamous cell carcinoma of the hand: Old fashion treatment Chatziantoniadis (Greece) (choosing the right treatment) Roxana del Aguila, Sabrina Negrete, P120 Giant invasive squamous cell Nora Molinari, Romina Cozzani carcinoma on erythrodermic (Argentina) mycosis fungoides Maria Politou, Andriani Tsiakou, Maria Pompou, Marina Papoutsaki, P115 Dermoscopy and optical coherence tomography in the evaluation of Ilectra Nikolaidou, Christina Antoniou relapses of immunocryosurgery (Greece) treated primary basal cell P121 New approach to high risk SCC carcinoma: A pilot study Staging: Can US and US guided Georgios Gaitanis, Ioannis Bassukas FNA substitute SNLB? (Greece) Ortansia Doryforou, Emmanouil Dimonitsas, Christina Kandaraki, P116 Locally advanced basosquamous Andriani-Eleni Trigka, Eirini Thymara, carcinoma responding to Penelope Korkolopoulou, George Vismodegib Champsas, Nikolaos Papadopoulos, Gurpreet Variaah, Demetrios Vasileios Stavrianos, Dim Papakostas, Ioannides, Aimilios Lallas, Elena Alexander J. Stratigos (Greece) Sotiriou, Elizabeth Lazaridou, Chryssa Papageorgiou, Zoe Apalla (Bulgaria, P122 Vismodegib as neoadjuvant Greece) treatment for locally- advanced basal-cell carcinoma of the eye in a P117 Aggressive metastatic SCC in a one-eyed patient: A case-report patient with chronic lymphocytic Alvaro Pantoja, David Cohn, Luis leukemia Marin, Rosemarie Bentjerodt, Polytimos Vassis, Maria Pompou, Fernando Silva, Nordiana Baruzzi Michaela Plaka, Alexander J. (Chile) Stratigos, Dorothea Polydorou, Varvara Theologi (Greece) P123 Melanoma in a patient with Gorlin- Goltz syndrome: A case report P118 An unusual clinical case of Irina Condrat, Rodica Cosgarea subungual squamous cell carcinoma (Romania) Efstratios Fragkos, Kalliopi Skarpelou, Epaminontas Kostopoulos, Erietta P124 An immunohistochemical study of Christofidou, Eirini Potouridou, laminin and collagen iv in basal cell Dorothea Polydorou, Alexander J. carcinoma Stratigos (Greece) Jelena Moisejenko-Golubovica, Valeria Groma, Anna Ivanova, P119 Basal cell carcinoma-surgical Raimond Karl (Latvia) restorations Matthaios Chatziantoniou,

54 13th Congress of the EADO • Athens, Greece Final Programme 55 EADO E-P European Association of Dermato Oncology

P125 Case report: Coexistence of solid P130 Mohs micrographic surgery made and adenoid basal cell carcinoma at easy the same anatomical site Ofer Arnon, Arsinoi Xanthinaki, Jelena Moisejenko-Golubovica, Anna Vasileios Pagkalos, Eldad Silberstein Ivanova, Janis Zarins, Valerie Groma (Israel, Greece) (Latvia) P131 The efficacy of vismodegib in P126 Secondary neoplasms associated treatment of advanced basal cell with nevus sebaceous of Jadassohn: carcinoma – An analysis of a case Retrospective study series Bohdan Lytvynenko, Serhii Vasylenko Florentina Silvia Delli, Theodoros (Ukraine) Sidiropoulos, Evangelia Kampouropoulou, Marina P127 Vismodegib treatment in a Papageorgiou, Konstantinos multidisciplinary team, Aarhus Efthimiadis, Ioanna Lefaki (Greece) Denmark - One year intention- to-treat cohort analysis and P132 Bowen’s disease: Five-year results recommendations of treatment with 5-fluorouracil Henrik F. Lorentzen, Martin Heje, cream, photodynamic therapy and Anne Birgitte Als (Denmark) surgical excision Maud Jansen, Diebrecht Appelen, P128 Photodynamic therapy for actinic Patty Nelemans, Nicole Kelleners- keratosis and basal cell carcinoma Smeets, Klara Mosterd (The using BF-200 ALA: Results of Netherlands) pivotal phase III trials and follow-up Rolf-Markus Szeimies, Uwe Reinhold, P133 Squamous cell carcinoma of the Thomas Dirschka, Axel Hauschild, skin - Cetuximab Response Ben Novak, Beate Schmitz, Hermann Andre Mansinho, Rita Sousa, Luis Lubbert, Colin A. Morton (Germany, Costa (Portugal) United Kingdom) P134 Cutaneous leishmaniasis and P129 Clinical and evolutionary basal cell carcinoma in a patient characteristics of cutaneous with acquired immune deficiency epidermoid carcinomas with syndrome Xeroderma pigmentosum in Kanella Kalapothakou, Maria Southern Tunisia Bourouni, Panagiota Arsenou, Argiro Fatma Dhouib, Hanene Ben Salah, Chatzimarinaki, Olga Kosmopoulou, Manel Bahri, Mounir Frikha, Hamida Charikleia Kouvidou, Efrosini Tsele Turki, Jamel Daoud (Tunisia) (Greece)

54 13th Congress of the EADO • Athens, Greece Final Programme 55 E-POSTERS CATALOGUE

P135 Study of L-max with reflectance P137 «Red face» therapy specificity confocal microscopy and HD- OCT Linda Kapteine (Latvia) Makiko Miyamoto, Francesca Perino, Alice Casari, Mariano Suppa, Marc P138 Actinic keratosis with reflectance Boone, Giovanni Pellacani, Josep confocal microscopy (RCM) and Malvehy, Véronique del Marmol optical coherence tomography (Belgium, Italy, Spain) (OCT): Agreement study Francesca Perino, Alice Casari, P136 Skin cancer and melanoma in Makiko Miyamoto, Véronique del patients with long lasting psoriasis Marmol, Giovanni Pellacani, Josep Laima Bloznelyte-Plesniene Malvehy (Spain, Italy, Belgium) (Lithuania)

RARE SKIN CANCERS

P139 A pyogenic granuloma like Kaposi’s P144 Solid cancer skin metastases sarcoma in the plantar region Hanene Ben Salah, Fatma Dhuib, Sinem Ayse Ornek, Emek Kocaturk, Manel Bahri, Tahia Boudawara, Omer Ozdemir, Zeynep Betul Erdem, Mounir Frikha, Jamel Daoud (Tunisia) Hatice Duman (Turkey) P145 Neo-Omphaloplasty as a 2nd stage P140 Metastatic sebaceous carcinoma of in abdominal wall reconstructive the anal margin surgery, following DFSP wide local Hanene Ben Salah, Hend Daoud, resection Manel Bahri, Hamida Turki, Mounir Eduardo Bertolli, Pedro Chiaramelli, Frikha, Jamel Daoud (Tunisia) Paulo Henrique Domingues Miran Brandao, Eduard Rene Brechtbuhl, P141 Malignant mesothelioma of the vulva Clovis Antonio Lopes Pinto, Joao Hanene Ben Salah, Manel Bahri, Pedreira Duprat Neto (Brazil) Fatma Dhuib, Hamida Turki, Jamel Daoud (Tunisia) P146 Lymphangioma-like Kaposi’s sarcoma. Case report P142 A case of mixed tumour of the skin with intracardiac metastasis Romina Cozzani, Fanny Bobadilla Hiu Kwan Carolyn Tang, Protty Majd, Godoy, Nora Molinari, Sabrina Owen Tilsley (United Kingdom) Negrete, Maria Celeste Ferrua, Carla Pulero, Roxana del Aguila (Argentina) P143 Angiosarcoma resembling hematoma – A case report P147 Case report: Rosai-Dorfman disease Dimitra Tasioula, Aikaterini Jelena Moisejenko-Golubovica, Ojar Malouhou, Dimitra Daskalopoulou, Lizan, Anna Ivanova, Valeria Groma George Anastasiadis (Greece) (Latvia)

56 13th Congress of the EADO • Athens, Greece Final Programme 57 EADO E-P European Association of Dermato Oncology

P148 National Cancer Institute of P153 Diagnostic challenges in Lithuania 10 year experience in rare cutaneous tumours – the management of Merkel cell spiradenocarcinomas carcinoma Teodora Eugenia Predescu, Irina Jaroslav Bublevic, Edita Salem, Olguta Orzan, Alexandra Baltruskeviciene (Lithuania) Sinziana Dumitru, Ana Maria Forsea, Calin Giurcaneanu (Romania) P149 Merkel cell carcinoma: A retrospective study for years 2006- P154 Brooke Spiegler syndrom: A 2016 at A. Sygros Hospital for special case Cutaneous and Venereal Diseases Cristina Mangas, Vittoria Espeli, Nikolaos Kostopoulos, Ioannis Sandra Leoni-Parvex, Monica Marnelakis, Alexander J. Stratigos, Taborelli, Daniel Hohl, Carlo Mainetti Gregorios Hampsas, Varvara (Switzerland) Theologi, Vasiliki Chasapi, Christina Antoniou (Greece) P155 PI3K p110 expression in Merkel cell carcinoma cell lines P150 Paraneoplastic upper trunk eczema Emil Chteinberg, Dorit Rennspiess, in a male patient with mammary Samantha Tauchmann, Veronique Paget’s disease Winnepenninckx, Ernst-Jan Speel, Diana Sabina Radaschin, Liliana Anna Kordelia Kurz, Martin Zenke, Gabriela Popa, Mara Madalina Axel zur Hausen (The Netherlands, Mihai, Alexandra Nicolescu, Manuela Germany) Simtea, Calin Giurcaneanu (Romania) P156 Aleukemic leukemia cutis with P151 Dermatofibrosarcoma Protuberans: blood dyscrasias A case report with an unusual Kanella Kalapothakou, Maria Politou, diascopic finding and critical George Polideras, Panagiota immunohistochemical analysis Arsenou, George Dryllis, Leonidas Kanella Kalapothakou, Achileas Marinos (Greece) Diakomopoulos, Spiros Papanikolaou, Ioanna Themeli, Efrosini Tsele, P157 Multimodal, individualized Charikleia Kouvidou (Greece) treatment of a post-irradiation breast angiosarcoma achieves P152 Treatment of Merkel cell carcinoma 8-year disease control: A case with pembrolizumab in a patient report with psoriasis and psoriatic arthritis Maritina Roppa (Germany) Lisa Roche, Michelle Murphy, Derek G. Power (Ireland)

56 13th Congress of the EADO • Athens, Greece Final Programme 57 E-POSTERS CATALOGUE

LATE BREAKING ABSTRACTS

P158 Reconstruction of the perineum P163 Paraneoplastic cutaneous and urogenital area manifestations: Case series in South D. Agorogiannis, S. Stavrianos, of Tunisia M. Kotrotsiou, N. Papadopoulos Ines Ayadi, Hanene Ben Salah, Rim (Greece) Kallel, Nabil Toumi, Alef Khanfir, Jamel Daoud, Mounir Frikha (Tunisia) P159 Spotlights on the photodynamic therapy P164 A case of cutaneous Leishmaniasis Foteini Chatzinasiou, Maria in a refugee patient in the hot Kosmadaki, Alexander J. Stratigos spot of Samos island: Clinical (Greece) presentation, diagnosis and treatment? P160 Unusual appearance of Kaposi Chrysi Kapelaki, Eleni Patsoula sarcoma on nose without HIV (Greece) infection Nahide Onsun, Burak Yalcin, Kadriye P165 Herpes simplex after threatment Sallahoglu, Zeynep Tosuner (Turkey) with ingenol mebutate for actinic cheilitis P161 Skin radionecrosis after cancer treatment Foteini Chatzinasiou, Maria Hanene Ben Salah, Basma Graja, Kosmadaki, Vasiliki Chasapi, Christina Manel Bahri, Jamel Daoud (Tunisia) Antoniou, Alexander J. Stratigos (Greece) P162 A case of Merkel cell carcinoma and review of the literature Serkan Yazici, Emel Bülbül Başkan, Şaduman Balaban Adim (Turkey)

58 13th Congress of the EADO • Athens, Greece Final Programme 59 EADO E-P European Association of Dermato Oncology

INDEX OF SPEAKERS, CHAIRPERSONS & AUTHORS

58 13th Congress of the EADO • Athens, Greece Final Programme 59 INDEX OF SPEAKERS, CHAIRPERSONS & AUTHORS

A Avgerinou Georgia | 36 Avraam Konstantinos | 46, 53 Adamicova Katarina | 44 Ayadi Ines | 58 Agarwala Sanjiv S. | 27, 29 Agianidis Christos | 51 Agiasofitou Efthymia | 44 B Agorogiannis Dimitrios | 58, 46 Bafaloukos Dimitrios | 27, 29, 78, 78, 78 Aigli Korfiati | 44 Bahali Anil Gulsel | 52 Ait-Belkacem Rima | 46 Bahri Manel | 43, 53, 53, 53, 55, 56, 56, 56, 58 Akhras Victoria | 47 Bailly Jean-Yves | 40 Alderling Magnus | 46 Balaban Adim Saduman | 58 Alejo Galindo Beatriz | 39 Balatoni Timea | 45, 52 Alfaro Christine | 40 Baldea Ioana | 51 Alkhateeb Zahra | 49 Baldueva Irina | 49 Aloui Zohra | 45 Baltas Eszter | 51 Als Anne Birgitte | 55 Baltruskeviciene Edita | 57 Amann Valerie C. | 40 Bamias Aristotelis | 29 Ameerally Phillip | 53, 53, 53 Barcelo Carla | 48, 48 Amici Jean-Michel | 40 Barreiro-Capurro Alicia | 23, 39 Amiel Jeanne | 38 Baruzzi Nordiana | 54 Anastasiadis George | 56 Basset-Seguin Nicole | 25, 25, 52 Andrades Evelyn | 38 Bassukas Ioannis | 34, 52, 53, 54 Andric Zoran | 49 Bastian Boris | 15, 18, 18 Anisimov Valentin | 49, 49 Bataille Veronique | 20, 20 Anthopoulos Tilemachos | 36 Battistella Maxime | 40 Antkowiak Ryszard | 51 Becker Jürgen | 13, 29, 29 Antkowiak Lukasz | 51 Befon Angeliki | 35, 52 Antoniou Christina | 35, 39, 43, 43, 44, 50, 52, Beggs Andrew | 38 54, 57, 58 Beissert Stefan | 28, 28, 42 Antoniou Iakovos | 50, 50 Bel Blandine | 47 Aoude Lauren | 41 Bell Debra | 51 Apalla Zoe | 22, 36, 41, 53, 54 Ben Hammouda Manel | 45 Appelen Diebrecht | 55 Ben Salah Hanene | 43, 53, 53, 53, 55, Aravantinos Gerasimos | 44, 44 56, 56, 56, 58, 58 Arenberger Petr | 22, 22, 26 Benea Vasile | 45 Arits Aimee | 40 Benedicic Ana | 49 Arnogiannaki Niki | 39 Benetatos Konstantinos | 46, 52 Arnon Ofer | 55 Bentjerodt Rosemarie | 54 Arrese Jorge E. | 43 Bernier Claire | 49, 49, 49 Arsenou Panagiota | 55, 57 Bernier Eduardo | 48, 50, 53, 56 Ascierto Paolo | 30, 30, 31, 42, 42, 52, 79, 79 Beylot-Barry Marie | 40 Athanasiadis Ilias | 31 Biyik Ozkaya Dilek | 52 Aubert Helene | 49 Blank Christian | 29, 31 Aubriot-Lorton Marie-Helene | 47 Bloznelyte-Plesniene Laima | 56 60 13th Congress of the EADO • Athens, Greece Final Programme 61 EADO European Association of Dermato Oncology

Bobadilla Godoy Fanny | 56 Champsas Gregory | 40 Bobrovska Martina | 44 Champsas Grigorios | 19, 51 Boccara Olivia | 38 Chapsa Maria | 30, 42 Boda Daniel | 45 Charalambidou Iris | 45 Boichuk Sergii | 47 Charitos Gregory | 46, 53 Boix Ramon | 48 Charpentier Sandrine | 48 Bolognesi Maddalena | 41 Charpidou Andrianni | 44 Boniface Katia | 48 Chasapi Vasiliki | 35, 39, 50, 52, 57, 58 Bonniaud Bertille | 47, 47 Chatziantoniadis Antonios | 54 Boone Marc | 56 Chatziantoniou Matthaios | 54 Borgmann Matthias | 43 Chatziioannou Sofia | 29 Borgogna Cinzia | 38 Chatzimarinaki Argiro | 55 Bosic Martina | 45 Chatzimichael Iakovoula | 44 Bosisio Francesca Maria | 30, 41 Chatzinasiou Foteini | 36, 58, 58 Bouassi Elodie | 47, 47 Cheng Phil | 47 Boudawara Tahia | 56 Chiaramelli Pedro | 56 Boukovinas Ioannis | 78 Christofidou Erietta | 39, 50, 54 Bouquin Rejane | 50 Chteinberg Emil | 38, 57 Bourouni Maria | 55 Chu Laura | 26, 40 Brandao Paulo Henrique Domingues Miran | 56 Cogrel Olivier | 40 Brasanac Dimitrije | 45 Cohn David | 54 Braun Ralph | 39 Condrat Irina | 50, 54 Brechtbuhl Eduard Rene | 56 Constantin Carolina | 45 Bregeon Barbara | 49 Cosgarea Rodica | 14, 54 Breschi M. Cristina | 42 Cosgarea Rodica Maria | 50 Brunner Georg | 39 Cosgun Betül | 21, 38 Brunner Martina | 44 Costa Luis | 55 Bublevic Jaroslav | 57 Courtier Anais | 46 Bulbul Baskan Emel | 58 Cozzani Romina | 54, 56 Bylaitė-Bučinskienė Matild | 34, 35 Cribier Bernard | 40 Curatolo Pietro | 38 C Czajka Milena | 48 Czirbesz Kata | 47 Cabral Marta | 53 Calati Fredrica | 38 Campana Luca | 38 D Canti Carles | 48, 48 Daguze Justine | 49 Carmignac Virginie | 38 Dalac-Rat Sophie | 47 Carpi Sara | 42 Danhauser-Riedl Susanne | 43 Carrera Cristina | 39 Daoud Hend | 56 Caruntu Constantin | 45 Daoud Jamel | 43, 53, 53, 53, 55, 56, 56, 56, 58, 58 Casari Alice | 56, 56 Daskalopoulou Dimitra | 56 Cassecuel Julie | 49 Davies Kelli-Jo | 38 Castro Yovanna | 48 Davies Nathaniel | 38 Cengiz Fatma Pelin | 45, 52 Dawson Keith | 40 Chaidemenos Georgios | 14 De Andrea Marco | 38 Chamalidou Eleni Panagiota | 45 de Brito Marianne | 21, 38 Champsas George | 54 de Macedo Mariana Petaccia | 48

60 13th Congress of the EADO • Athens, Greece Final Programme 61 INDEX OF SPEAKERS, CHAIRPERSONS & AUTHORS

Eigentler Thomas | 46 Eldershaw Suzy | 38 Elloumi Moez | 43 De Vries Esther | 49 Emiroglu Nazan | 45, 52 Deinlein Teresa | 39 Engelmann David | 47 del Aguila Roxana | 54, 56 Erdem Zeynep Betul | 56 del Marmol Velonique | 14, 17, 17, 56, 56 Espeli Vittoria | 57 Delli Florentina Silvia | 55 Essafi Benkhadir Khadija | 45 Demerdzieva Zdravka | 50 Evangelou Evangelos | 17 Demirkesen Cuyan | 52 Evangelou George | 36 Denis Marc | 50, 50, 50 Ezzedine Khaled | 40 Deskoulidi Parthena | 22, 39, 46, 49, 52 Dessinioti Clio | 25, 52 F Deterlizzi Francesca | 38 Fabra Angels | 48 Dewar Donald | 41, 45 Faivre Laurence | 38 Dhouib Fatma | 53, 53, 53, 55 Falcao Ana Carolina Anacleto | 53 Dhuib Fatma | 56, 56 Farazi Paraskevi | 45 Diakomopoulos Achileas | 57 Farcette Florian | 46 Diamantopoulos Panagiotis | 44 Fekkas Nikos | 51 Diamantopoulos Pantelis | 39, 46, 49, 52 Ferrandiz-Pulido Carla | 38 Dima Monica | 43 Ferrua Maria Celeste | 56 Dimier Natalie | 52 Fetisovova Zelmira | 44 Dimitriou Florentia | 23, 39 Fiedler Eckhard | 46 Dimonitsas Emmanouil | 26, 40, 44, 46, 49, 51, 53, 54 Fil`chakov Feodosiy | 47 Dirschka Thomas | 17, 17, 22, 39, 55 Filip Adriana | 51 Dizman Didem | 52 Fisher David E. | 19 Djedovic Jelena | 49 Fittipaldo Alberto | 52 Doryforou Ortansia | 40, 44, 46, 54 Flaherty Keith T. | 42 Dousset Lea | 26, 40, 48 Flessas Ioannis | 49 Drainas Denis | 44 Florez Juanpablo | 49 Dreno Brigitte | 13, 21, 40, 40, 42, 48, 49, 49, 49, Floros Theofanis | 28, 28 50, 50 ,52 Flotte Thomas | 51 Dryllis George | 57 Fogli Stefano | 42 Duarte Carlos | 49 Foley Catherine C. | 51 Dubbini Nevio | 42 Forsea Ana-Maria | 14, 14, 20, 23, 43, 43, 43, 57 Duman Hatice | 56 Fosko Scott | 40, 40 Dumitru Alexandra-Sinziana | 43, 57 Fostira Florentia | 46 Dummer Reinhard | 22, 27, 29, 31, 39, 40, 46, 47, 78 Fragkos Efstratios | 54 Duprat Neto Joao Pedreira | 48, 50, 53, 56 Fraitag Sylvie | 38 Dutriaux Caroline | 48 Frangia-Tsivou Konstantina | 18, 46 Frangoulis Marios | 51 E Frank Markus H. | 41 Eben Jonathan | 38 Frank Natasha Y. | 41 Economidi Afroditi | 43, 43 Frauchiger Anna | 39 Efthimiadis Konstantinos | 55 Frikha Mounir | 55, 56, 56, 58 Eggermont Alexander M. M. | 21, 21, 77, 77 Furst Katharina | 47

62 13th Congress of the EADO • Athens, Greece Final Programme 63 INDEX OF SPEAKERS, EADO European Association of CHAIRPERSONS & AUTHORS Dermato Oncology

G Guminski Alexander | 40 Gumulka Martin | 46 Gafton Georgy | 49, 49 Gupta Girish | 17 Gaitanis Georgios | 27, 52, 53, 54 Gusdorf Laurence | 40 Galvao Bruno Luiz | 50 Gutzmer Ralf | 13, 29, 39, 46, 77 Gandini Sara | 17, 17 Garbe Claus | 12, 14, 15, 23, 31, 36, 46, 47 Garcia-Diez Irene | 38 H Garcia-Patos Vicenc | 38 Haanen John | 46 Gariglio Marisa | 38 Hadker Nandini | 49 Garzarolli M. | 42 Hampsas Gregorios | 57 Gasmi Ammar | 45 Hansson Johan | 52 Gassenmaier Maximilian | 47 Harries Sarah | 38 Gatius Sonia | 48 Harwood Catherine | 22, 41, 41 Gehl Julie | 38 Hassel Jessica | 46 Gelfond Mark | 49 Hauschild Axel | 13, 19, 21, 27, 40, 40, 42, 52, 55, 77, 77 Geller Alan | 14, 14 Hayward Nicholas | 18, 18, 30, 41 Georgescu Simona-Roxana | 45 Heilborn Johan | 46 Georgiou Sophia | 20 Heje Martin | 55 Gershenwald Jeffrey E. | 19, 28 Herbreteau Guillaume | 50 Gezsi Andras | 47 Hernandez-Munoz Inmaculada | 38 Ghorbel Abdelmonem | 53, 53, 53 Hernandez-Ruiz Eugenia | 38 Ghorbel Lilia | 43 Herreros Judit | 48 Gilberg Frank | 40, 40 Hertig Christian | 52 Gimeno Javier | 38 Hillen Uwe | 51 Gimeno Ramon | 38 Hocevar Marko | 49 Giuliani Rosa | 23 Hoeller Christoph | 12, 12, 27, 30 Giurcaneanu Calin | 43, 43, 57, 57 Hofbauer Günther | 34 Giurcaneanu Calvin | 43 Hohl Daniel | 57 Gkouveris Panagiotis | 50 Höiöm Veronica | 41 Goebeler Matthias | 46 Horimoto Kouhei | 46 Goerdt Sergej | 46 Gogas Helen | 21, 21, 21, 28, 29, 39, 44, 50, 78, 78, 78, 79 I Goldinger Simone | 46, 47 Ilijin Ivana | 51 Goldinger Simone Maria | 39 Ioannides Demetrios | 41, 53, 54 Gomez Ignacio | 48 Ioannides Dimitrios | 17 Gondry Odrade | 51 Iqbal Urooj | 53 Gorka Eszter | 47 Ivanova Anna | 54, 55, 56 Gorski Kevin S. | 39 Ivantsov Alexander | 49 Gouveris Panagiotis | 46 Ivert Lina | 46 Grafanaki Katerina | 44 Graja Basma | 58 J Grob Jean Jacques | 13, 17, 26, 31, 39, 40, 40, 40, 52 Jaberg-Bentele Nicoletta | 46 Groma Valeria | 54, 56 Jacquemin Clement | 48 Groma Valerie | 55 Jaka Ane | 38 Grunhagen Dirk | 38, 52 Janjic Zlata | 47 Guillen Julie | 40 62 13th Congress of the EADO • Athens, Greece Final Programme 63 INDEX OF SPEAKERS, CHAIRPERSONS & AUTHORS

Keeble Claire | 41, 45 Kefala Maria | 50 Keim Ulrike | 46 Kelleners-Smeets Nicole | 40, 55 Jansen Maud | 26, 40, 55 Kemeny Lajos | 51 Jansen Yanina | 51 Kentepozidis Nikolaos | 46, 53 Janssen Renske | 53 Khammari Amir | 48, 49, 50 Jaukovic Ljiljana | 48 Khanfir Alef | 58 Jeudy Geraldine | 47, 47 Kidonakis Michael | 39 Jevremovic Ljubica | 51 Kinsler Veronica | 12, 20 Jimbow Kowichi | 45 Kittler Harald | 14, 14, 20, 20, 36 Johansson Peter | 41 Kjerkegaard Ulrik | 46, 46 Jonsson Göran | 41 Klonaris Christos | 46 Josselin Nicolas | 49 Klop Martin | 38 Jouan Thibaud | 38 Knobler Robert | 34, 35, 43 Knol Anne Chantal | 49, 50, 50 K Kocaturk Emek | 56 Kadurina Mira | 50 Koekelkoren Fabienne | 40 Kakagia Despoina | 41 Koliarakis Nikolaos | 27 Kalampokas Athanasios | 36 Kontos Christos | 44 Kalapothakou Kanella | 55, 57, 57 Korkolopoulou Penelope | 41, 53 Kallel Rim | 58 Korkolopoulou Pinelopi | 54 Kamiya Shiori | 46 Korogiannos Athanasios | 46, 50 Kampilafkos Panagiotis | 30, 41 Korovin Sergii | 47, 47 Kampouropoulou Evangelia | 55 Kosmadaki Maria | 58, 58 Kandaraki Christina | 54 Kosmopoulou Olga | 55 Kandolf-Sekulovic Lidija | 22, 23, 23, 48, 51, 51 Kostenko Elena | 52 Kapasi Farhana | 53, 53, 53 Kostopoulos Epameinondas | 51, 54 Kapelaki Chrysi | 58 Kostopoulos Nikolaos | 57 Kapiris Ioannis | 44, 46 Kotrotsiou Maria | 46, 52, 58 Kapteine Linda | 56 Koufopoulos Nikolaos | 52 Karagiannidis Ioannis | 44 Koumakis Georgios | 39, 46 Karagiannis Sophia N. | 28 Koutsoukou Theofani | 54 Karambidou Konstantina | 43 Kouvidou Charikleia | 55, 57 Karl Raimond | 54 Kovacevic Predrag | 53 Karonidis Athanasios | 50 Kovacs Peter | 47 Karoui Habib | 45 Krasagakis Konstantinos | 35 Kasarakis Dimitrios | 45 Krauss Babett | 43 Kassini Maria | 50, 50 Kremic Zorana | 51 Kato Junji | 46 Kudchadkar Ragini | 40 Katoulis Alexander | 14, 50, 50 Kuentz Paul | 38 Katsambas Andreas | 25 Kukushkina Mariia | 47, 47 Katsarou Alexandra | 25 Kukushkina Svitlana | 47, 47 Katsouyanni Klea | 52 Kunstfeld Rainer | 25, 26, 40, 40, 52 Kaufmann Corina | 47 Kunte Christian | 38 Kaufmann Roland | 19, 19, 32, 32 Kurz Anna Kordelia | 38, 57

64 13th Congress of the EADO • Athens, Greece Final Programme 65 INDEX OF SPEAKERS, EADO European Association of CHAIRPERSONS & AUTHORS Dermato Oncology

Kvistborg Pia | 46 Lorigan Paul | 12 Kydonakis Michael | 46, 50 Lubbert Hermann | 55 Kyprianou Demetra | 45 Lud Nikalai | 45 Luu Maxime | 47 L Lytvynenko Bohdan | 55 Labeille Bruno | 40, 40 Lacouture Mario | 40 M Lallas Aimilios | 12, 12, 36, 36, 41, 53, 54 Macedo Mariana Petaccia | 50 Landi Maria Teresa | 28, 28 Machado Valter Junio Fiuza | 50 Lanfredini Simone | 38 Macia Anna | 48, 48 Lapins Jan | 46 Madu Max | 52 Larkin James | 42 Magic Zvonko | 51 Larsabal Maiana | 48 Mainetti Carlo | 57 Larsson Thomas | 41, 41 Maio Michele | 77 Laschos Konstantinos | 44 Maiques Oscar | 48, 48 Laskarakis Apostolos | 31 Majd Protty | 56 Lazaridou Elizabeth | 14, 41, 53, 54 Makris Nikolaos | 48 Le Moigne Marie | 49 Makrutzki Martina | 40, 40 Le Naour Sarah | 49 Malecki Maciej | 48 Lear John | 34, 40, 79, 79 Malouhou Aikaterini | 56 Lebas Eve | 43 Maltzaris Nikolaos | 46, 52 Lebbe Celeste | 13, 25, 25 Malvehy Josep | 12, 19, 23, 36, 39, 39, 56, 56 Lefaki Ioanna | 18, 55 Mangana Joanna | 39, 47 Leigh Irene M. | 34, 34 Mangas Cristina | 57 Leiter Ulrike | 46 Manoli Sofia Magdalini | 53 Lekovic Dragana | 47 Mansinho Andre | 55 Lemoigne Marie | 49 Mantzourani Marina | 50 Leoni-Parvex Sandra | 57 Manuel Manuarii | 46 Levesque Mitch P. | 47 Margaritescu Irina | 43, 43, 43 Levesque Mitchell | 46 Marin Luis | 54 Lewis Karl | 42, 42 Marinkovic Marija | 47 Liakou Paraskevi | 49 Marinos Leonidas | 35, 43, 43, 44, 57 Lianidou Evi S. | 29 Marnelakis Ioannis | 57 Licitra Lisa | 52 Marples Maria | 41, 45 Liew See Hwang | 38 Marquardt Stefan | 47 Linardou Helena | 27, 30 Marti Aurelie | 48 Liordou Fotini | 44 Marti Rosa Maria | 48, 48 Liszkay Gabriella | 45, 47, 52 Maruani Annabe | 38 Liu Kate | 39 Mascaró-Galy Jose Manuel | 39 Livingstone Elisabeth | 25, 51 Masferrer Emili | 38 Lizan Ojar | 56 Matias-Guiu Xavier | 48, 48 Logotheti Stella | 47 Matsko Dmitriy | 49 Lon Ganna | 47 McArthur Grant | 42, 42 Long Georgina | 12, 27, 28, 79, 79, 79 McCarthy Siobhan | 51 Longo Catarina | 12, 17 McKenna Edward | 42 Lopez Hector | 49 McMurray Jack | 38 Lorentzen Henrik F. | 55 McNally Virginia | 42 64 13th Congress of the EADO • Athens, Greece Final Programme 65 INDEX OF SPEAKERS, CHAIRPERSONS & AUTHORS

Newton-Bishop Julia | 18, 18 Neyns Bart | 51 Nghiem Paul | 28, 79 Nguyen-Kim Thi Dan Linh | 46 Meier Friedegund | 31, 31, 42 Nicolaidou Electra | 19 Melegh Krisztina | 47 Nicolescu Alexandra | 57 Meneses Ximena | 49 Nicolescu Alin | 43 Michielin Olivier | 29, 31 Niculi Ancuta | 50 Migden Michael | 22, 39 Nieri Paola | 42 Mihai Mara Madalina | 43, 57 Niessner Heike | 47 Mijuskovic Zeljko | 51, 51 Nikkels Arjen | 43 Milicevic Sara | 49 Nikolaidou Ilectra | 54 Mitran Cristina-Iulia | 45 Nikolaidou Thaleia | 46, 52 Mitran Madalina-Irina | 45 Nikolaou Vasiliki | 34, 43, 43, 44, 44, 44 Mitrovic M. | 51 Nikolic Jelena | 47 Miyamoto Makiko | 56, 56 Nikolin Borislava | 47 Mohr Peter | 14, 31, 79, 79 Novak Ben | 55 Moisejenko-Golubovica Jelena | 54, 55, 56 Ntasiou Dimitra | 36, 36 Molinari Nora | 54, 56 Montenegro Maia Fernanda | 45 O Moredo Luciana Facure | 50 Ocsai Henriette | 51 Moreno Sara | 48 Odili Joy | 38, 47 Moreno-Ramírez David | 32, 32 Olah Judit | 35, 35, 51 Mortier Laurent | 52 Olencki Thomas | 40 Morton Colin A. | 55 Olivera Carlotta | 38 Moss Paul | 38 Olteanu Diana | 51 Mosterd Klara | 38, 40, 53, 55 Onsun Nahide | 45, 52, 52, 58 Mouret Jean-Francois | 46 Orfanos Nikolaos | 50 Mueller Daniel | 49 Orgaz Jose Luis | 48 Mun Yong | 40, 42 Orlovius Martin | 43 Muresan Larisa Georgiana | 50 Ornek Sinem Ayse | 56 Murphy Michelle | 51, 57 Ortiz-Romero Pablo | 35 Murray Duncan | 21, 38 Orzan Olguta | 57 Murray Samuel | 18 Orzan Olguta Anca | 43 Myasnyankin Mikhail | 49, 49, 49 Oshyvalova Olena O. | 52 Ostafiichuk Vasyl | 47 N Østerdal Marie Louise | 41, 41 Naccarati Alessio | 42 Ostojic Nikola | 51 Nagore Eduardo | 17, 22 Ozdemir Omer | 56 Neagu Monica | 45 Neamonitos Konstantinos | 50 P Nedic Z. M. | 51 Pagkalos Vasileios | 55 Negrete Sabrina | 54, 56 Palivets Andrii | 47 Nekhaeva Tatiana | 49 Panagiotopoulos Antonios | 52 Nelemans Patty | 40, 55 Panayiotides Ioannis | 50 Nenu Iuliana | 51 Panayotou Petros | 32

66 13th Congress of the EADO • Athens, Greece Final Programme 67 INDEX OF SPEAKERS, EADO European Association of CHAIRPERSONS & AUTHORS Dermato Oncology

Panczel Gitta | 45, 47 Pistolas Konstantinos | 39, 49 Panosa Anais | 48 Plaka Michaela | 39, 50, 54 Panoutsopoulou Ioanna | 25, 44, 44, 44 Planken Simon | 51 Pantoja Alvaro | 54 Pogorzelska-Antkowiak Anna | 51 Paoli John | 26, 32 Polideras George | 57 Papadavid Evangelia | 35, 43, 43 Polini Beatrice | 30, 42 Papadavid N. | 58 Politou Maria | 51, 54, 57 Papadopoulos Nikolaos | 41, 54 Polydorou Dorothea | 14, 39, 50, 54, 54 Papadopoulos Othon | 39, 41, 49, 50, 51 Polyzois Panagiotis | 36 Papadopulos Nikolaos A. | 49 Pompou Maria | 51, 54, 54 Papaeuthymiou Fotini | 45 Popa Liliana Gabriela | 43, 57 Papageorgiou Chrysoyla | 30, 41 Popescu Ioana | 43 Papageorgiou Chryssa | 54 Postow Michael | 78 Papageorgiou Marina | 55 Potouridou Eirini | 54 Powell Kathryn | 38 Papaioannou Dionissios | 44 Power Derek G. | 57 Papakostas Dim | 54 Prakoshyn Andrei | 45 Papakostas Dimitrios | 36, 40 Predescu Teodora | 43, 43 Papanikolaou Spiros | 57 Predescu Teodora Eugenia | 57 Papas Thanos | 47 Prey Sorilla | 48 Papoutsaki Marina | 54 Pritchard Antonia | 41 Pardini Barbara | 42 Puig Susana | 14, 18, 36, 39, 40, 40, 48 Pasqua Nicolas | 46 Pujol Ramon M. | 38 Patel Girish | 20, 38 Pulero Carla | 56 Patsatsi Aikaterini | 25 Putzer Brigitte M. | 47 Patsoula Eleni | 58 Pazaiti Anastasia | 49 Q Peach Howard | 41, 45 Quaglino Pietro | 34, 38, 43 Pearce Hayden | 38 Quereux Gaelle | 48, 49, 49, 49, 50, 50 Pec Juraj | 44 Pehamberger Hubert | 13, 19 Pehoiu Andra | 43 R Pellacani Giovanni | 56, 56 Raaijmakers Marieke | 46 Perez Solene | 46 Radaschin Diana Sabina | 43, 57 Peric Barbara | 49 Radevic Tatjana | 51 Perino Francesca | 56, 56 Radulovic Marija | 48 Peris Ketty | 34 Rajovic Milica | 48, 51, 51 Perry Krista | 49 Rambert Jerome | 48 Petrakopoulou Dora | 39 Ramelyte Egle | 47 Petrakopoulou Theodora | 50 Rauschenberg R. | 42 Peuvrel Lucie | 48, 49, 49, 49, 50, 50 Reinders Marieke | 38 Reinhold Uwe | 39, 55 Pfister Herbert | 38 Rennspiess Dorit | 38, 57 Pichler Nadja | 39 Riahi Chebbi Ichrak | 45 Pickett Cheryl A. | 39 Ribas Antoni | 42 Pijuan Jordi | 48 Ribero Simone | 18, 21, 38 Pinto Clovis Antonio Lopes | 48, 50, 56 Rigopoulos Dimitrios | 22, 22, 50, 50 Pisklakova Tatiana | 52

66 13th Congress of the EADO • Athens, Greece Final Programme 67 INDEX OF SPEAKERS, CHAIRPERSONS & AUTHORS

Schindler Sabrina | 46 Schmitz Beate | 55 Schuler Georg | 46 Scolyer Richard A. | 18, 18, 28 Riviere Jean-Baptiste | 38 Scorilas Andreas | 44 Robert Caroline | 27, 29, 31, 79 Seferos Emmanouil | 44 Robinson Alyss | 30, 41, 45 Seifert Lars | 44 Roche Lisa | 51, 57 Sekulic Aleksandar | 40 Rodgaard Jes C. | 46, 46 Seneschal Julien | 48 Rodriguez Lopez Jose Neptuno | 45 Seremet Teofila | 51 Roediger Alexander | 23 Serra-Guillen Carlos | 41, 41 Rogers Gary | 40, 40, 40 Sgontzou Themis | 44 Romanini Antonella | 42 Sgouros Dimitrios | 12, 36, 50, 50 Romero Marta | 48 Shaukat Athanasios | 44 Rompoti Natalia | 27, 51 Sheinin Maxim | 49 Rooney Isabelle | 42 Shumilina Katerina | 47 Roppa Maritina | 57 Siakantaris Marina | 35 Rotunno Roberta | 38 Sibaud Vincent | 25 Roulias Athanasios | 44 Sidiropoulos Theodoros | 55 Rozzeboom Marieke | 40 Sijan Goran | 48 Ryll Bettina | 23 Silberstein Eldad | 55 Silva Diego Greatti Vaz | 50 S Silva Fernando | 54 Sacco Joseph | 39 Simtea Manuela | 57 Sachlas Athanasios | 43 Sinnberg Tobias | 47 Saiag Philippe | 29, 35, 35, 36 Sinx Kelly | 53 Saint-Jean Melanie | 48, 49, 49, 49, 50 Skafida Evelina | 39 Salem Irina | 43, 57 Skarpelou Kalliopi | 54 Sallahoglu Kadriye | 58 Skov Torsten | 41, 41 Samoylenko Igor | 39 Sober Arthur J. | 14 Sanchez Herman | 49 Soman Arundhati | 40 Santacana Maria | 48 Sonagli Marina | 53 Sanz-Moreno Victoria | 48 Sondak Vernon K. | 19, 19, 19, 31 Sarbu Maria Isabela | 45 Sorensen Jens A. | 46, 46 Sato Sayuri | 46 Soria Xavier | 48 Sauer Christopher | 38 Sorlin Arthur | 38 Sawada Masahide | 46 Sotiriadis Dimitrios | 34 Scalia Carla | 41 Sotiriou Elena | 17, 41, 53, 54 Scarisbrick Julia | 34, 38, 43 Souid Soumaya | 45 Schadendorf Dirk | 12, 25, 26, 27, 29, 39, 40, 40, Soupos Nikolaos | 44 51, 79, 79, 79 Soura Efthymia | 18, 22, 39, 50 Schaller Jorg | 41 Sousa Rita | 55 Scharffetter-Kochanek Karin | 41 Speel Ernst-Jan | 38, 57 Schiffelers Lisa | 38 Stachowiak Natalia | 48 Schimming Tobias | 51 Stadler Rudolf | 35, 35, 43, 77, 77, 77, 77

68 13th Congress of the EADO • Athens, Greece Final Programme 69 INDEX OF SPEAKERS, EADO European Association of CHAIRPERSONS & AUTHORS Dermato Oncology

Stas Marguerite | 41 Tesselaar Margot | 38, 52 Statelova Dagmar | 44 Testori Alessandro | 19, 27, 27, 32 Stathopoulos Constantinos | 44 Themeli Ioanna | 57 Stauber Jonathan | 46 Theoleyre Sandrine | 50, 50 Stavrianeas Nikolaos | 36 Theologi Varvara | 54, 57 Stavrianos S. | 58 Thiolat Denis | 48 Stavrianos Spiros | 46 Thomas Ioannis | 47 Stavrianos Spyridon | 52 Thuru Xavier | 46 Stavrianos Vasileios | 54 Thymara Eirini | 40, 54 Stavropoulos Panagiotis | 25 Tilsley Owen | 56 Steder Marc | 47 Toll Agusti | 20, 38 Stefanaki Christina | 22, 39, 50 Topukcu Dizman Bugce | 52 Stefanaki Irene | 18, 20, 46 Tosuner Zeynep | 52, 58 Steinberg Ira | 49 Toumi Nabil | 58 Stepic Nenad | 48 Trakatelli Myrto | 17 Stichenwirth Martin | 46 Triantafyllopoulou Ioanna | 44, 44, 44 Stockfleth Eggert | 26, 26, 34, 41, 41, 79, 79 Trifonopoulos Dimitrios | 39 Stockton Joanne | 38 Trigka Andriani-Eleni | 40, 54 Stojkovic-Filipovic Jelena | 45 Troost E. | 42 Stolle Lars B. | 46, 46 Tsankov Nikolay | 50 Stratigos Alexander J. | 15, 25, 25, 28, 36, 36, 39, Tsele Efrosini | 55, 57 41, 43, 43, 44, 44, 44, 46, Tsiakou Andriani | 51, 54 50, 51, 52, 52, 53, 54, 54, Tsimpoukis Sotirios | 44 54, 57, 58, 58, 78, 78 Su Ozlem | 52, 52 Tsintzou Panagiota | 53 Supic Gordana | 51 Tsorova Aggeliki | 53 Suppa Mariano | 56 Tsoutsos Dimosthenis | 32, 50 Surcel Mihaela | 45 Tudor Diana | 51 Swan Bonnie | 47 Turki Hamida | 53, 55, 56, 56 Syrigos Konstantinos | 44 Tuting Thomas | 46 Szavcsur Peter | 45 Tzanetakou Vassiliki | 52 Szeimies Rolf-Markus | 34, 55 U T Uhara Hisashi | 46 Taborelli Monica | 57 Ulrich Claas | 46 Taieb Alain | 48 Takahashi Hitomi | 46 V Tampa Mircea | 45 Vabres Pierre | 21, 38, 47, 47 Tampouri Ioanna | 47 Vakirlis Efstratios | 41, 53 Tang Hiu Kwan Carolyn | 38, 56 Vakis Giorgos | 51 Tasioula Dimitra | 56 Valk Gerlof | 38 Tauchmann Samantha | 57 Vallee Audrey | 48, 50 Telesheva Larisa | 52 Vallejo Carmen | 53 Tembulkar Tanuf | 49 Valls Joan | 48 Teramoto Yukiko | 46 van Akkooi Alexander | 38, 52

68 13th Congress of the EADO • Athens, Greece Final Programme 69 INDEX OF SPEAKERS, CHAIRPERSONS & AUTHORS

X van den Oord Joost | 41 Xanthinaki Arsinoi | 55 van Geel Michel | 53 Xydakis Emmanouil | 44 van Veenendaal Linde | 20, 38, 52 Varga Anita | 51 Y Variaah Gurpreet | 41, 54 Yalcin Burak | 58 Vassis Polytimos | 54 Yamada Mao | 46 Vasylenko Serhii | 55 Yazici Serkan | 58 Velasco Anna | 48 Yebenes Mireia | 38 Vergier Beatrice | 40 Yildiz Pelin | 52 Verhoef Cornelis (Cees) | 38, 52 Yoo Jinah | 38 Vermeer Maarten H. | 34, 34 Yoo Simon | 40 Vieira Ricardo | 20, 36 Vilella Ramon | 48 Z Virós Amaya | 18 Zajkowska Agnieszka | 48 Voudouri Dimitra | 43, 44, 44 Zalaudek Iris | 12, 12, 20, 23, 39 Vougiouklakis Dimitrios | 46 Zarins Janis | 55 Vukanovic Tatjana | 51 Zarkadas Georgios | 39, 46, 50 Zenke Martin | 38, 57 W Zgajnar Janez | 49 Wade Ryckie | 41, 45 Zhu Qian | 40, 42 Wadt Karin | 41 Zhukavetz Aliaxandr | 45 Whiteman David | 17, 19 Zloty David | 40, 40 Willemze Rein | 34 Zografos George | 49 Wilson Brian J. | 41 Zoras Odysseas | 27, 27 Winnepenninckx Veronique | 38, 57 Zouboulis Christos | 44 Wolf Ingrid | 39 Zouridaki Eftychia | 44 Wollina Uwe | 46 Zubulis Christos | 46 Wouters Jasper | 41 zur Hausen Axel | 20, 38, 57 Wylomanski Sophie | 50 Zurac Sabina | 45

70 13th Congress of the EADO • Athens, Greece Final Programme 71 INDEX OF SPEAKERS, EADO European Association of CHAIRPERSONS & AUTHORS Dermato Oncology

SPONSORS & EXHIBITORS

70 13th Congress of the EADO • Athens, Greece Final Programme 71 ACKNOWLEDGEMENTS

The Organising Committee of the 13th Congress of the EADO gratefully acknowledges the following companies for their support in the success of the Congress:

PLATINUM SPONSORS

GOLD SPONSORS

SILVER SPONSORS

BRONZE SPONSORS

EXHIBITORS-SPONSORS

72 13th Congress of the EADO • Athens, Greece Final Programme 73 EADO European Association of Dermato Oncology ACKNOWLEDGEMENTS CORPORATE PROFILES

AMGEN ONCOLOGY Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. } For more information, visit www.amgen.com and follow us on www.twitter.com/amgen

BRISTOL-MYERS SQUIBB Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis. Since 2009, we have delivered 12 new products to patients with serious diseases. Four of these are biologic products, including groundbreaking immunotherapies that use the body’s immune system to fight cancer. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. We are recognized as having one of the most productive R&D pipelines in the industry. What sets us apart as a BioPharma leader is our commitment to helping patients prevail over serious diseases and our focus on finding innovative medicines to combat those diseases. Generating new ideas and thinking differently are at the heart of everything we do – making a difference in the lives of patients. } For more information, visit www.bms.com

INCYTE Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. World-class science and the pursuit of R&D excellence drive Incyte’s business and its commitment to improving the lives of patients with cancer and other diseases. Incyte has a broad and diverse clinical portfolio that includes 14 development candidates against 11 different molecular targets. Headquartered in Wilmington, Delaware, Incyte Corporation has operations in Switzerland and eight other European countries. } For more information, visit www.incyte.com. Follow @Incyte on Twitter at https://twitter.com/Incyte

72 13th Congress of the EADO • Athens, Greece Final Programme 73 CORPORATE PROFILES

LEO PHARMA LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide. } For more information, visit www.leo-pharma.com

MERCK-PFIZER ALLIANCE Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The alliance is focused on developing high-priority international clinical programs to investigate avelumab, as a monotherapy, as well as combination regimens, and is striving to find new ways to treat cancer. } For more information, visit www.merckgroup.com

MSD For 125 years, MSD has been a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. } For more information, visit www.msd.com

NORGINE Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016 the company generated product sales of approximately €300 million, as well as significant royalty and milestone income. Norgine specialises in gastroenterology, hepatology, cancer and supportive care. Is active in the field of sentinel node detection in breast cancer, melanoma and oral squamous cell carcinoma. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply. Norgine is headquartered in the Netherlands, owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France. } For more information, visit www.norgine.com

74 13th Congress of the EADO • Athens, Greece Final Programme 75 EADO European Association of Dermato Oncology CORPORATE PROFILES

NOVARTIS Novartis Group has a leading position in the Greek Pharmaceuticals Sector. It has been active in Greece for more than 20 years, with a diversified portfolio including innovative medicines (Novartis), holistic eye care (Alcon) and generics (Sandoz). Novartis’ portfolio includes more than 50 innovative products, many of which are leaders in therapeutic areas such as cardiometabolic diseases, the Immunology and Dermatology, the Neurosciences, the respiratory disease, Ophthalmology, Oncology and Haematology. In Novartis we are inspired by patients and we focus our Corporate Responsibility work in two key areas: expanding access to healthcare and doing business responsibly. We utilize science-based innovation to deliver better patient outcomes. Our vision is to contribute to the evolution of medical practice, always with high levels of responsibility and integrity. In the period 2013-2015 the company invested 138.2 mio Euros in Greek society, through R & D, tax payments, payroll, suppliers, donations and sponsorships, while our investments to approximately 200 clinical trials is more than 18 mio. Euros. We support patients by implementing innovative programs to improve their quality of life and their survival expectancy, in collaboration with scientific and patient community. We consistently support social and scientific initiatives such as drug donations, free medical exams, early access programs to innovative treatments, donations to Public Hospitals and University Clinics for conducting scientific research programs, Also we realize disease awareness and prevention programs, patient rights campaigns and support many patient associations. } For more information, visit www.novartis.gr

PIERRE FABRE Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2015, it generated 2,208 million euros in net sales, of which 58% came from its international business and 57% from its dermo- cosmetics division. Pierre Fabre, which has always been headquartered in the South- West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,000 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2015, Pierre Fabre dedicated almost 200 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics. With its brands, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Elancyl, Pierre Fabre Health Care, Pierre Fabre Oral Care and Naturactive, Pierre Fabre is the market leader in France for skin care, hair care and oral care products sold in pharmacies and drugstores. Marketed globally, Eau Thermale Avène is the leading dermo-cosmetics brand in Europe and in Asia. In oncology, Pierre Fabre generates over 90% of its revenue outside France. Pierre Fabre is mostly owned (86%) by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees. } For more information, visit www.pierre-fabre.en

74 13th Congress of the EADO • Athens, Greece Final Programme 75 CORPORATE PROFILES

ROCHE Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. } For more information, please visit www.roche.com

TAKEDA PHARMACEUTICAL COMPANY Takeda Pharmaceutical Company Limited is a global, research and development- driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. } Additional information about Takeda is available through its corporate website, www.Takeda.com

76 13th Congress of the EADO • Athens, Greece Final Programme 77 EADO European Association of Dermato Oncology CORPORATE PROFILES SPONSORED SESSIONS

WEDNESDAY, MAY 3, 2017 N. SKALKOTAS HALL

14:30-15:00 INDUSTRY SATELLITE LECTURE 1 Supported by The ALCANZA trial – A new dawn in the treatment of relapsed/refractory CTCL 14:30-14:35 Welcome and introduction Rudolf Stadler (Minden, Germany) 14:35-14:50 The ALCANZA trial – Treatment of relapsed/refractory CTCL with brentuximab vedotin Rudolf Stadler (Minden, Germany) 14:50-14:59 Interrogating the ALCANZA data – What does it mean for patients and the CTCL treatment paradigm? Rudolf Stadler (Minden, Germany) 14:59-15:00 Closing remarks Rudolf Stadler (Minden, Germany)

MC2 HALL

14:30-15:30 INDUSTRY SATELLITE SYMPOSIUM 1 Supported by Understanding the melanoma microenvironment Chair: Alexander Eggermont (Paris, France)

14:30-14:35 Welcome and introductions Alexander Eggermont (Paris, France) 14:35-14:55 Treatment combinations in melanoma: Where are we now and where are we going? Axel Hauschild (Kiel, Germany) 14:55-15:15 The tumor microenvironment: Beyond the T cell Michele Maio (Siena, Italy) 15:15-15:30 Panel discussion, Q&A, Closing remarks All faculty

BANQUET HALL 17:30-18:00 INDUSTRY SATELLITE LECTURE 2 Supported by What do oncolytic immunotherapies mean for patients with early metastatic melanoma? Chair: Axel Hauschild (Kiel, Germany) Speaker: Ralf Gutzmer (Hannover, Germany)

76 13th Congress of the EADO • Athens, Greece Final Programme 77 SPONSORED SESSIONS

WEDNESDAY, MAY 3, 2017 N. SKALKOTAS HALL 17:30-18:00 INDUSTRY SATELLITE LECTURE 3 Individualized treatment strategy in melanoma Supported by Chair: Helen Gogas (Athens, Greece) Speaker: Ioannis Boukovinas (Thessaloniki, Greece)

THURSDAY, MAY 4, 2017 BANQUET HALL 12:45-13:45 INDUSTRY SATELLITE LUNCH SYMPOSIUM 2 * Melanoma 2017: Update in Immuno-Oncology Supported by Chair: Dimitris Bafaloukos (Athens, Greece)

12:45-12:50 Welcome and introduction Dimitris Bafaloukos (Athens, Greece) 12:50-13:05 Adjuvant therapy: Where are we today? Helen Gogas (Athens, Greece) 13:05-13:30 Considerations in clinical practice in metastatic melanoma Michael Postow (New York, USA) 13:30-13:45 Hot topic debate Faculty panel 13:45 Summary and close Dimitris Bafaloukos (Athens, Greece) * Don’t forget to pick up your lunch box BANQUET HALL 15:30-16:30 INDUSTRY SATELLITE SYMPOSIUM 3 Supported by The evolution of melanoma management: Where to from here? Chair: Alexander J. Stratigos (Athens, Greece) 15:30-15:40 Welcome and introduction Alexander J. Stratigos (Athens, Greece) 15:40-16:00 Evolution of the science and the melanoma treatment landscape Reinhard Dummer (Zurich, Switzerland) 16:00-16:20 Optimising treatment selection: When, with what, and in whom? Helen J. Gogas (Athens, Greece) 16:20-16:30 Discussion and Q&A

78 13th Congress of the EADO • Athens, Greece Final Programme 79 EADO European Association of Dermato Oncology

N. SKALKOTAS HALL 18:30-19:30 INDUSTRY SATELLITE SYMPOSIUM 4 Immuno-intervention in patients with Merkel Supported by cell carcinoma Chair: Dirk Schadendorf (Essen, Germany) 18:30-18:40 Welcome and introduction Dirk Schadendorf (Essen, Germany) 18:40-18:55 Rationale for immuno-intervention in Merkel cell carcinoma Paul Nghiem (Seattle, USA) 18:55-19:20 Treatment approaches for Merkel cell carcinoma Caroline Robert (Paris, France) 19:20-19:30 Q&A and close Dirk Schadendorf (Essen, Germany)

FRIDAY, MAY 5, 2017 BANQUET HALL

12:45-13:45 INDUSTRY SATELLITE LUNCH SYMPOSIUM 5 * Supported by Shaping the future together: Treatment of metastatic melanoma Chair: Georgina Long (Sydney, Australia) 12:45-12:55 What does the future look like for patients with metastatic melanoma? Georgina Long (Sydney, Australia) 12:55-13:05 Combining targeted therapy with immunotherapy: A rational approach Peter Mohr (Buxtehude, Germany) 13:05-13:15 Targeted therapy and immunotherapy, a potential combination for the future: The early clinical evidence Paolo Ascierto (Naples, Italy) 13:15-13:45 Achieving the best outcomes in metastatic melanoma today: The experts’ experience Helen Gogas (Athens, Greece), Peter Mohr (Buxtehude, Germany), Paolo Ascierto (Naples, Italy) Facilitated by Georgina Long (Sydney, Australia) * Don’t forget to pick up your lunch box MC2 HALL 15:30-16:30 INDUSTRY SATELLITE SYMPOSIUM 6 Optimising actinic keratosis diagnosis and management: The scale of the problem Chairs: Eggert Stockfleth (Bochum, Germany) Supported by John Lear (Manchester, United Kingdom) Speakers: Eggert Stockfleth (Bochum, Germany) John Lear (Manchester, United Kingdom)

78 13th Congress of the EADO • Athens, Greece Final Programme 79 CONGRESS VENUE AND EXHIBITION FLOOR PLANS

LEVEL - 1

COMPANY BOOTH No 3GEN INC. 04 AMGEN ONCOLOGY 06 BRISTOL-MYERS SQUIBB 07 CANFIELD SCIENTIFIC 18 DEKAZ 02 DERMA MEDICAL SYSTEMS 08A EADO INFORMATION DESK 08B EPSILON HEALTH 20 IGEA MEDICAL 03

80 13th Congress of the EADO • Athens, Greece Final Programme 81 EADO European Association of Dermato Oncology CONGRESS VENUE AND EXHIBITION FLOOR PLANS

LEVEL - 2

COMPANY BOOTH No INCYTE CORPORATION 16 LA ROCHE POSAY 17 LEO PHARMA 21 MERCK-PFIZER ALLIANCE 22 MSD 19 NORGINE 05 NOVARTIS 15 PIERRE FABRE HELLAS 01 WISEPRESS 09 & 10

80 13th Congress of the EADO • Athens, Greece Final Programme 81 ΝΟΤΕS

Immuno-Oncology

82 13th Congress of the EADO • Athens, Greece Final Programme 83

67935_EADO_Programme_Advert_v2a_RTP.indd 1 4/7/17 1:15 PM CHECK OUT THE

TAKEDA EVENT @ EADO 2017!

THE ALCANZA TRIAL – A NEW DAWN IN THE TREATMENT OF

RELAPSED/REFRACTORY CTCL Industry-sponsored satellite lecture Industry-sponsored satellite lecture What do oncolytic immunotherapies mean for WEDNESDAY 3RD MAY 2017 What do oncolytic immunotherapies mean for 14:30-15:00 hrs patients with early metastatic melanoma? N. Skalkotas Hall, Megaron Athens International Conference Centre, Wednesday 3 May 2017, 17.30–18.00 Athens, Greece Banquet Hall, Megaron Athens International Conference Centre Banquet Hall, Megaron Athens International Conference Centre Athens, Greece Athens, Greece Chair: Axel Hauschild, Germany Chair: Axel Hauschild, Germany Speaker: Ralf Gutzmer, Germany Speaker: Ralf Gutzmer, Germany Silver partner Silver partner

Amgen (Europe) GmbH AmgenDammstrasse (Europe) GmbH 23 DammstrasseCH-6300 Zug 23 CH-6300Switzerland Zug WE ASPIRE www.amgen.comSwitzerland TO CURE CANCER. Organized by Takeda Pharmaceuticals International AG. www.amgen.com 1000cranesofhope.com © 2017 Takeda Pharmaceuticals International AG GLO/ADC/2017-00007b Date of Preparation: April 2017 © 2017 Amgen Inc. All rights reserved © 2017 AmgenSC-EU-AMG678-00022-0317 Inc. All rights reserved SC-EU-AMG678-00022-0317

AMG1785 EADO ad 170x240mm.indd 1 29/03/2017 16:21 786208686-001_EADO PROGRAMME AD v2.indd 1 05/04/2017 16:30 AMG1785 EADO ad 170x240mm.indd 1 29/03/2017 16:21 CHECK OUT THE

TAKEDA EVENT @ EADO 2017!

THE ALCANZA TRIAL – A NEW DAWN IN THE TREATMENT OF

RELAPSED/REFRACTORY CTCL Industry-sponsored satellite lecture Industry-sponsored satellite lecture What do oncolytic immunotherapies mean for WEDNESDAY 3RD MAY 2017 What do oncolytic immunotherapies mean for 14:30-15:00 hrs patients with early metastatic melanoma? N. Skalkotas Hall, Megaron Athens International Conference Centre, Wednesday 3 May 2017, 17.30–18.00 Athens, Greece Banquet Hall, Megaron Athens International Conference Centre Banquet Hall, Megaron Athens International Conference Centre Athens, Greece Athens, Greece Chair: Axel Hauschild, Germany Chair: Axel Hauschild, Germany Speaker: Ralf Gutzmer, Germany Speaker: Ralf Gutzmer, Germany Silver partner Silver partner

Amgen (Europe) GmbH AmgenDammstrasse (Europe) GmbH 23 DammstrasseCH-6300 Zug 23 CH-6300Switzerland Zug WE ASPIRE www.amgen.comSwitzerland TO CURE CANCER. Organized by Takeda Pharmaceuticals International AG. www.amgen.com 1000cranesofhope.com © 2017 Takeda Pharmaceuticals International AG GLO/ADC/2017-00007b Date of Preparation: April 2017 © 2017 Amgen Inc. All rights reserved © 2017 AmgenSC-EU-AMG678-00022-0317 Inc. All rights reserved SC-EU-AMG678-00022-0317

AMG1785 EADO ad 170x240mm.indd 1 29/03/2017 16:21 786208686-001_EADO PROGRAMME AD v2.indd 1 05/04/2017 16:30 AMG1785 EADO ad 170x240mm.indd 1 29/03/2017 16:21 in Multiple Tumor Types ECHOThe Clinical Trial Program Is Now Enrolling HAVE YOU HEARD? the use(s)under investigation. There isno guaranteethatthesecompounds willbecomecommercially availablefor established and the investigationalcompoundsare notapproved forcommercial use. The ef cacy andsafetyoftheinvestigationalcompoundsdiscussed havenotbeen 00027423+800 To orto moreabouttheECHO program learn enroll inatrial, call tumor types. ( ECHO a selective IDO1 inhibitor of novel the use the investigating program immunotherapy development epacadostat, clinical © 2017,Incyte Corporation. Allrightsreserved. INC-1221 02/17EU/OTHR/M/17/0023 5 clinical trials exploring 13 tumor types E Breast cancer endometrium Adenocarcinoma of the Glioblastoma gastroesophageal cancer Gastric and cancer Colorectal pacadostat pacadostat with PD-1/PD-L1 inhibitors currently recruitingpatients. are Several trials investigating in combination epacadostat

or e-mail C Visit ECHOclinicaltrials.com to learn more. learn to ECHOclinicaltrials.com Visit

linical development in H [email protected] , in combination with other therapies across a broad range of range abroad across therapies other with combination , in Non–Hodgkin lymphoma Non–Hodgkin Hodgkin lymphoma Head and neck cancer neck and Head Non–small cellNon–small lung cancer Melanoma Epacadostat: inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1) 1 indoleamine-2,3-dioxygenase of inhibitor ematology and O and ematology

An investigational, selective oral investigational, selective An ncology) is Incyte’s global Ovarian cancer Urothelial cancer Renal cell carcinoma

Παρακαλείστε να ανατρέξετε στην πλήρη Περίληψη Χαρακτηριστικών Προϊόντος (Π.Χ.Π.) Προϊόντος Χαρακτηριστικών Περίληψη πλήρη στην ανατρέξετε να Παρακαλείστε ΕΠΙΒΙΩΣΗ ΦΑΡΜΑΚΟΕΠΑΓΡΥΠΝΗΣΗ: 210 2828812 210 ΦΑΡΜΑΚΟΕΠΑΓΡΥΠΝΗΣΗ: Θέρμη, 01 570 Μουδανιών, Ν. - Θεσσαλονίκης χλμ. 12ο Θεσσαλονίκης: Γραφείο 2811712 210 Τηλ. Μεταμόρφωση, 51 144 Αθηνών-Λαμίας, Οδού Εθνικής χλμ. 12ο A.E.Β.Ε. (Hellas) Novartis Τηλ. 2310 424039 2310 Τηλ.

ΧΡΟΝΟΣ

TAF-MEK_ADV_001_05/2016/GR1605476557 Lectus adv. Παρακαλείστε να ανατρέξετε στην πλήρη Περίληψη Χαρακτηριστικών Προϊόντος (Π.Χ.Π.) Προϊόντος Χαρακτηριστικών Περίληψη πλήρη στην ανατρέξετε να Παρακαλείστε ΕΠΙΒΙΩΣΗ ΦΑΡΜΑΚΟΕΠΑΓΡΥΠΝΗΣΗ: 210 2828812 210 ΦΑΡΜΑΚΟΕΠΑΓΡΥΠΝΗΣΗ: Θέρμη, 01 570 Μουδανιών, Ν. - Θεσσαλονίκης χλμ. 12ο Θεσσαλονίκης: Γραφείο 2811712 210 Τηλ. Μεταμόρφωση, 51 144 Αθηνών-Λαμίας, Οδού Εθνικής χλμ. 12ο A.E.Β.Ε. (Hellas) Novartis Τηλ. 2310 424039 2310 Τηλ.

ΧΡΟΝΟΣ

TAF-MEK_ADV_001_05/2016/GR1605476557 Lectus adv. CURRENTLY ENROLLING: First-line cohort for JAVELIN Merkel 200 A Phase 2, multicenter, international, single-arm, open-label study of avelumab (MSB0010718C) for subjects with metastatic Merkel cell carcinoma (mMCC) who have not received prior systemic treatment for metastatic disease

FOR MORE INFORMATION: www.clinicaltrials.gov (NCT02155647)

The JAVELIN clinical trial program studies avelumab in Phases 1-3, both as monotherapy and in combination with other agents. The program includes diseases with large patient populations as well as rare diseases with high unmet needs.

Avelumab is being investigated for treatment of various diseases. E cacy and safety of this product is still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Please check with your local market authorization label for country-specifi c information. Clinical trial information is available at www.clinicaltrials.gov. Avelumab has not yet been approved for any use outside of the U.S.

This information is current as of March 2017.

March 2017 US/AVE/0317/0142(1)

US-AVE-0317-0142_R02_APDL_JavelinMerkel_JA.indd 1 4/11/17 1:48 PM CURRENTLY ENROLLING: First-line cohort for JAVELIN Merkel 200 A Phase 2, multicenter, international, single-arm, open-label study of avelumab (MSB0010718C) for subjects with metastatic Merkel cell carcinoma (mMCC) who have not received prior systemic treatment for metastatic disease

FOR MORE INFORMATION: www.clinicaltrials.gov (NCT02155647)

The JAVELIN clinical trial program studies avelumab in Phases 1-3, both as monotherapy and in combination with other agents. The program includes diseases with large patient populations as well as rare diseases with high unmet needs.

Avelumab is being investigated for treatment of various diseases. E cacy and safety of this product is still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Please check with your local market authorization label for country-specifi c information. Clinical trial information is available at www.clinicaltrials.gov. Avelumab has not yet been approved for any use outside of the U.S.

This information is current as of March 2017.

March 2017 US/AVE/0317/0142(1)

US-AVE-0317-0142_R02_APDL_JavelinMerkel_JA.indd 1 4/11/17 1:48 PM

A Roche-sponsored satellite symposium at the European Association of Dermato Oncology 2017

CONTENTS SHAPING THE FUTURE WELCOME ADDRESS...... 3 COMMITTEES...... 4 TOGETHER GENERAL INFORMATION...... 5-8

SOCIAL PROGRAMME...... 8

SCIENTIFIC INFORMATION...... 9-10

SCIENTIFIC PROGRAMME WEDNESDAY, MAY 3, 2017 TREATMENT OF PROGRAMME OVERVIEW...... 11 PROGRAMME ...... 12-15 METASTATIC THURSDAY, MAY 4, 2017 MELANOMA PROGRAMME OVERVIEW...... 16

PROGRAMME ...... 17-23

FRIDAY, MAY 5, 2017 Friday, 5 May 2017 | 12:45–13:45 | Banquet Hall PROGRAMME OVERVIEW...... 24 Megaron Athens International Congress Centre PROGRAMME ...... 25-32 Chaired by Georgina Long, Melanoma Institute of Australia, Australia SATURDAY, MAY 6, 2017 PROGRAMME OVERVIEW...... 33 12:45–12:55 What does the future look like for patients with metastatic melanoma? PROGRAMME ...... 34-36 Georgina Long, Melanoma Institute of Australia, Australia

12:55–13:05 Combining targeted therapy with immunotherapy: A rational approach FREE COMMUNICATIONS CATALOGUE ...... 38-42 Peter Mohr, Elbekliniken Stade Buxtehude, Germany E-POSTERS CATALOGUE ...... 43-58

INDEX OF SPEAKERS, CHAIRPERSONS & AUTHORS ...... 59-70 13:05–13:15 Targeted therapy and immunotherapy, a potential combination for the future: The early clinical evidence SPONSORS & EXHIBITORS SECTION Paolo Ascierto, IRCCS National Tumour Institute Fondazione G Pascale, Italy 13:15–13:45 Achieving the best outcomes in metastatic melanoma today: ACKNOWLEDGEMENTS ...... 72 The experts’ experience CORPORATE PROFILES ...... 73-76 Helen Gogas, University of Athens, Greece SPONSORED SESSIONS Peter Mohr, Elbekliniken Stade Buxtehude, Germany Paolo Ascierto, IRCCS National Tumour Institute Fondazione G Pascale, Italy WEDNESDAY, MAY 3, 2017 ...... 77-78 Facilitated by Georgina Long THURSDAY, MAY 4, 2017 ...... 78-79

FRIDAY, MAY 5, 2017 ...... 79

EXHIBITION FLOOR PLAN ...... 80-81 NP/COBI/1703/0001d melanoma_3_0417 Date of Preparation April 2017 EADO European Association of Dermato Oncology

3 - 6 May 2017 Athens Greece Megaron Athens International Conference Centre

FINAL PROGRAMME

Visit BMS at Booth No 5 to learn more

Bristol-Myers Squibb A.E. Attica 49-53 & Propontidos 2, 152 35 Vrilissia, P.O. Box 63883 - 152 35 Vrilissia Attica Tel: +30 210 60 74 300 & +30 210 60 74 400, Fax: +30 210 60 74 333 G.E.MI 7453601000 Before prescribing please consult the SmPC that is provided by the Marketing Authorization Holder.

You can help make medicines safer by reporting all adverse events for all medicines, by completing the ‘Yellow Card’

7356GR1700165-01 03/17 © 2017 Bristol-Myers Squibb Company. www.eado2017.org OPDIVO® and YERVOY® and the related logos are trademarks of Bristol-Myers Squibb Company.

106271 EADO Athens Programme Book Advert v3.0 2017.03.16.indd 1 27/03/2017 09:59